Spoluzakladatel BitMEX Arthur Hayes očekává, že HYPE bude zaostávat za ETH a ZEC kvůli rostoucí konkurenci mezi decentralizovanými burzami s perpetual futures.
Arthur Hayes expects HYPE to deliver weaker returns than Ethereum and Zcash from current levels. The view follows months of position changes, including his full exit from HYPE in June. HYPE is pulling back toward the moving average that has supported its entire 2026 rally. Ethereum’s deep discount to its record high is central to the Hayes argument. Arthur Hayes, the BitMEX co-founder who now serves as chief investment officer of crypto fund Maelstrom, said in an October 16 interview that Hyperliquid’s HYPE token could underperform Ethereum (ETH) and Zcash (ZEC), pointing to growing competition among decentralized perpetual futures exchanges, platforms where traders open leveraged bets on prices without an expiry date. A week later, HYPE trades near $78.26, about 20% below its $97.99 record after four straight weeks of lower highs. Hayes added that he respects what the Hyperliquid team has built and would still use its products, but he no longer wants to own the token, which makes the comment the latest step in a shift that started in June.
From a $150 Target to a Full Exit Hayes on HYPE in 2026
● March: Discusses a $150 HYPE scenario ● May: Names HYPE, NEAR and ZEC his “holy trinity” ● June 4-5: Sells HYPE, NEAR and then ZEC ● August: Calls ETH his preferred trade ● October 16: Says HYPE could lag ETH and ZEC In March, Hayes argued that record open interest in HIP-3 markets, which let developers list new perpetual contracts on Hyperliquid, could carry HYPE to $150. By late May he was grouping it with NEAR and ZEC as his favorite trio, praising the token’s revenue model and its access to traditional assets. Less than two weeks later, on June 4, he sold his HYPE and NEAR positions, citing higher energy prices, the risk that large AI listings would pull liquidity away from crypto and a weaker macro backdrop. A day later he exited ZEC as well, saying a vulnerability in Zcash’s Orchard pool meant the network could not cryptographically prove that extra coins had never been created.
The speed of the reversal drew criticism, and on-chain investigator ZachXBT accused Hayes of using his followers as exit liquidity. In August, Hayes disclosed that Maelstrom had bought HYPE in the low $30s and sold around $75, adding that ETH could rise three to five times relatively quickly. By the October 16 interview, ETH and ZEC were back at the center of his thinking, despite his June exit from Zcash.
Why ETH Looks Cheaper on His Math The case rests on relative valuation, since Hyperliquid generated roughly $429 million in revenue between January 1 and September 15, and nearly all protocol fees go toward buying HYPE on the open market, which ties the token directly to trading activity. Investors now widely recognize that link, so in Hayes’ view much of the success is already reflected in the price. Rival perpetual exchanges pose the specific risk: every share of volume they win reduces the fees Hyperliquid collects, and with them the size of the buybacks that support HYPE.
Ethereum sits on the other side of that trade, since it remains the main settlement layer for decentralized finance yet has lagged smaller assets for most of the past year, and it trades about 51% below its August 2025 peak. His Zcash thesis is different in kind, built on the idea that financial privacy gains value as governments, large tech companies and AI systems track more economic activity. Both are investment views, and ZEC in particular carries its own liquidity and regulatory risks.
HYPE Leans on Its 21-Week Average HYPE/USDT weekly chart. Source: Alexander Stefanov / TradingView The 21-week exponential moving average at $72.85 has guided the whole 2026 advance. HYPE reclaimed it in January, has closed above it every week since and bounced off it in July before the August breakout. The same line marked the turn in late 2025, when losing it in October and November preceded a three-month slide to $20. Together with the 0.382 Fibonacci retracement at $68.38, it forms a $68.4-72.9 support band that also overlaps the range where price spent most of May through July.
Momentum has weakened even as HYPE set a far higher high in September than in June, yet the relative strength index peaked near 83 in late May and reached only about 70 at the record, meaning buyers pushed with less force on the final leg. The reading now sits at 56.2, below its signal line, although still above 50, which fits a cooling trend rather than a reversal. A weekly close below $68.4 would point to $59.24 and then the $50-51 area, where the 0.618 level meets the rising 50-week average. Holding the band and reclaiming $85-88 would reopen a test of $97.99, with $119.07 as the next extension above it.
ETH Is Stuck Between Two Averages ETH/USDT weekly chart. Source: Alexander Stefanov / TradingView Ethereum trades at $2,407.69, inside a narrow cluster formed by the 50-week EMA at $2,419.68 and the 200-week EMA at $2,462.74. Sellers stopped the September rally at $2,749, which is both the 0.618 Fibonacci level and the measured target of the double bottom ETH built near $1,550-1,600 in June and July. Volume during the pullback has stayed below the August breakout, suggesting profit-taking rather than heavy selling, while the RSI at 52.85 shows no clear direction. A close above $2,463 would turn the cluster into support and open a second test of $2,749, then $3,171. Repeated closes below the 50-week average would send price back toward the $2,149 neckline.
ZEC Defends a Month-Long Floor ZEC/USDT weekly chart. Source: Alexander Stefanov / TradingView Zcash bounced 9.25% this week to $1,235.40, extending a four-week stretch in which every weekly low held above the 0.382 level at $1,047.48. The upper wick to $1,368 shows sellers remain active above the 0.236 level at $1,289.17. ZEC trades about 90% above its 50-week EMA, and its RSI peaked near 78 at the September record versus roughly 95 during the November 2025 rally, a gap that marks weaker buying pressure at higher prices. A close above $1,289 would put the $1,680 record back in view, with $2,130 beyond it. Losing $1,047 would expose $852, then the $647-657 zone where the 0.618 level and the 50-week average meet.
Sunday’s Closes Will Test the Rotation The weekly candles close on Sunday, October 25. If HYPE ends the week below $72.85 while ETH settles above its 200-week average, the charts would show the rotation Hayes describes, with money moving from a token near its highs toward one still far below. Hyperliquid’s buyback size depends directly on its share of perpetual trading volume, so monthly market share data across decentralized derivatives venues offers a more concrete test of the competition argument than price alone.
Hayes has reversed course on all three tokens within months this year, and blockchain analysts track wallets linked to him and Maelstrom closely. Any renewed buying of HYPE, or new selling of ETH or ZEC, would likely appear in on-chain transfer data before he comments on it publicly.
Alex is a financial markets journalist and co-founder of Millennial Media Group, and he's spent close to ten years trying to answer one stubborn question: what's really driving this? It started in 2016, when Bitcoin refused to make sense to him - and rather than shrug, he stayed with it until it did. That patience became his method. He's less interested in what an asset is doing today than in the plumbing behind it: how liquidity flows, where risk hides, what a chart is quietly telling you that the headline isn't. That lens eventually stretched well past crypto into traditional markets, because the same forces - fear, leverage, incentives, timing - show up everywhere once you know how to look. Most coverage, in his view, insults the reader by stopping at the surface. Price up, price down, moving on. He'd rather leave someone genuinely understanding a move than merely informed that it happened. His path into markets ran through a Tourism degree at New Bulgarian University - proof, maybe, that curiosity beats credentials. With more than 200 deep analyses and over 10,000 articles behind him, he still walks away from most trading days having learned something he didn't know that morning.
Kinder Morgan ve čtvrtletí končícím v září 2026 zvýšil tržby o 9,3 % na 4,53 miliardy USD a vykázal EPS ve výši 0,35 USD, čímž překonal odhady analytiků.
For the quarter ended September 2026, Kinder Morgan (KMI - Free Report) reported revenue of $4.53 billion, up 9.3% over the same period last year. EPS came in at $0.35, compared to $0.29 in the year-ago quarter.
The reported revenue represents a surprise of +3.52% over the Zacks Consensus Estimate of $4.38 billion. With the consensus EPS estimate being $0.33, the EPS surprise was +6.06%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Kinder Morgan performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Realized weighted average oil price: $/68.65 versus the two-analyst average estimate of $/71.4.Realized weighted average NGL price: $/34.48 versus $/35.06 estimated by two analysts on average.Terminals - Liquids leasable capacity: 78.70 MMBBL versus the two-analyst average estimate of 78.60 MMBBL.NGL sales volumes - net: 9.88 millions of barrels of oil compared to the 9.8 millions of barrels of oil average estimate based on two analysts.CO2 sales volumes - net: 0.27 Bcf/D compared to the 0.30 Bcf/D average estimate based on two analysts.Total oil production - net: 27.07 millions of barrels of oil versus 28.2 millions of barrels of oil estimated by two analysts on average.Terminals - Bulk transload tonnage: 13.50 MMTon versus 12.65 MMTon estimated by two analysts on average.Segment EBDA- Natural gas Pipelines: $1.5 billion versus $1.41 billion estimated by three analysts on average.Segment EBDA- Terminals: $385 million compared to the $284.75 million average estimate based on three analysts.Segment EBDA- Products Pipelines: $172 million compared to the $290.54 million average estimate based on three analysts.Segment EBDA- CO2: $172 million versus the three-analyst average estimate of $195.07 million.View all Key Company Metrics for Kinder Morgan here>>>
Shares of Kinder Morgan have returned +7.9% over the past month versus the Zacks S&P 500 composite's -1.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
In the latest trading session, Jabil (JBL - Free Report) closed at $273.97, marking a +2.45% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.52%. Meanwhile, the Dow experienced a drop of 1.24%, and the technology-dominated Nasdaq saw a decrease of 0.21%.
Shares of the electronics manufacturer witnessed a loss of 13.93% over the previous month, trailing the performance of the Computer and Technology sector with its loss of 7.7%, and the S&P 500's loss of 1.21%.
Analysts and investors alike will be keeping a close eye on the performance of Jabil in its upcoming earnings disclosure. The company is expected to report EPS of $4.1, up 43.86% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $11.03 billion, indicating a 32.76% growth compared to the corresponding quarter of the prior year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $17.61 per share and a revenue of $44.62 billion, signifying shifts of +34.53% and +24.11%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for Jabil. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 6.07% increase. Jabil presently features a Zacks Rank of #1 (Strong Buy).
In terms of valuation, Jabil is currently trading at a Forward P/E ratio of 15.18. This expresses a discount compared to the average Forward P/E of 21.93 of its industry.
Meanwhile, JBL's PEG ratio is currently 0.75. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Electronics - Manufacturing Services industry currently had an average PEG ratio of 0.75 as of yesterday's close.
The Electronics - Manufacturing Services industry is part of the Computer and Technology sector. Currently, this industry holds a Zacks Industry Rank of 20, positioning it in the top 9% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
CRH má 29. října 2026 zveřejnit výsledky; analytici očekávají zisk na akcii (EPS) ve výši 2,14 USD, což je meziročně o 3,17 % méně, a tržby ve výši 11,72 miliardy USD, tedy o 5,87 % více.
In the latest close session, CRH (CRH - Free Report) was down 1.78% at $84.89. This change lagged the S&P 500's 0.52% loss on the day. Elsewhere, the Dow saw a downswing of 1.24%, while the tech-heavy Nasdaq depreciated by 0.21%.
Coming into today, shares of the building material company had gained 2.94% in the past month. In that same time, the Construction sector lost 6.53%, while the S&P 500 lost 1.21%.
The investment community will be paying close attention to the earnings performance of CRH in its upcoming release. The company is slated to reveal its earnings on October 29, 2026. The company's earnings per share (EPS) are projected to be $2.14, reflecting a 3.17% decrease from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.72 billion, up 5.87% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $5.83 per share and a revenue of $39.6 billion, demonstrating changes of +4.67% and +5.75%, respectively, from the preceding year.
Investors might also notice recent changes to analyst estimates for CRH. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 1.24% downward. As of now, CRH holds a Zacks Rank of #3 (Hold).
Looking at valuation, CRH is presently trading at a Forward P/E ratio of 14.83. This expresses a discount compared to the average Forward P/E of 17.08 of its industry.
Also, we should mention that CRH has a PEG ratio of 1.57. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. Building Products - Miscellaneous stocks are, on average, holding a PEG ratio of 1.5 based on yesterday's closing prices.
The Building Products - Miscellaneous industry is part of the Construction sector. This industry currently has a Zacks Industry Rank of 204, which puts it in the bottom 18% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
FedEx has joined the governing council of Hedera, a public distributed ledger network that positions itself as a neutral enterprise-grade trust layer. This development has drawn attention to HBAR, Hedera’s native token, especially as it trades around $0.08. Crypto commentator Rip The Bull has suggested that increasing participation from multinational corporations signals the network’s growing potential.
Major companies strengthen Hedera governanceFedEx, one of the world’s largest logistics companies, now operates a node on the Hedera network and holds an equal vote on the council alongside technology giants including Google, IBM, and Dell. The council system provides decentralized governance, with each member overseeing network decisions and performance. FedEx’s chief digital officer has referred to the platform as a “neutral enterprise grade trust layer.”
The Hedera governing council can include up to 39 organizations from diverse industries. Notable participants since 2019 include Boeing and, more recently, energy provider Repsol. While these institutions have a stake in shaping the network, the extent of their actual usage of Hedera’s services remains unclear.
FedEx’s position on Hedera’s council, joined by peers such as Google and IBM, highlights expanding enterprise involvement in decentralized networks, but does not confirm the scale of their network transactions.
Although such partnerships bring credibility, a seat on the council does not necessarily indicate the company’s day-to-day activity or financial transactions on the Hedera platform.
Banking infrastructure and institutional integrationSwiss digital asset infrastructure company Taurus has integrated Hedera’s technology into its services. Taurus now offers more than 40 regulated banks and financial institutions access to custody, token issuance, and smart contract features on the Hedera network.
Rip The Bull notes that Tauras’s clients can now hold and stake HBAR, but clarified that availability does not automatically mean active staking or new assets have been launched by these institutions using Hedera.
Mini dictionary: Taurus is a Swiss fintech company specializing in digital asset infrastructure, including custody, tokenization, and blockchain solutions for regulated banks and financial institutions.
The commentator referenced an April 2027 target for an on-chain delivery milestone tied to a United Kingdom wholesale-markets initiative. However, the source material does not specifically mention Hedera, suggesting this date is a broader industry benchmark rather than a confirmed Hedera rollout.
InstitutionRole on HederaConfirmed Network UsageFedExCouncil Member, Node OperatorUndisclosedGoogleCouncil MemberUndisclosedTaurusService IntegratorEnables access for 40+ banksRepsolCouncil MemberUndisclosedHBAR price analysis and future projectionsAccording to the latest YouTube analysis, HBAR’s price stands near $0.08. The commentary places $0.09 as the level required to reclaim a “200” indicator, referring to a technical metric relevant among traders. The host also identifies a weekly Fibonacci target near $0.80 and predicts a longer-term move to $1, though these outcomes are based solely on market analysis, not on any news from participating corporations.
For investors, the central question remains whether growing enterprise participation will translate to increased network use and rising demand for HBAR. While major institutions are joining the Hedera council and integrating its services, sustained token demand will depend on actual activity and adoption across these networks.
The difference between enterprise participation and network usage will determine whether Hedera’s governance partnerships shift into real demand for HBAR.
ETF společnosti Canary Capital sledující Hedera zaznamenal během 12 měsíců kumulativní nárůst čistých přílivů o 69 % a jeho aktiva dosáhla 113 milionů USD, přestože HBAR za stejné období klesl o 52 %.
Canary Capital’s exchange-traded fund (ETF), which tracks Hedera (HBAR), has continued its listing on NASDAQ with steady trading activity through a challenging year for the digital asset. Despite HBAR losing 52% of its value over the past twelve months and falling 28% year-to-date, the ETF posted a notable 69% cumulative increase in net inflows for the same period.
Institutional Resilience Amid Market DeclineThis persistent influx signals strong institutional commitment, even as market sentiment around HBAR remains weak. The ETF’s asset base reached $113 million, reflecting consistent demand. However, net flows have recently stagnated, with three consecutive weeks without any new inflows in the last quarter.
Last week saw net outflows of $558,980, attributed to larger investors reducing their positions amid geopolitical uncertainty. This withdrawal follows a period when the ETF was attracting several hundred thousand dollars per week, suggesting that while institutional participants are not broadly exiting, some have scaled back their exposure.
This slow but steady shift points to large investors methodically adjusting allocations in response to prolonged bearish trends, rather than abandoning their positions entirely.
A segment of institutional participants is treating current HBAR price levels as an opportunity, guided by indicators like the Market Value to Realized Value (MVRV) index. When this metric turns negative, it signals the chance to purchase at what could be considered discounted prices, as earlier investors may have absorbed much of the earlier sell-off.
Mini dictionary: MVRV index — The Market Value to Realized Value (MVRV) index measures the ratio between a cryptocurrency’s total market cap and its realized cap. A negative MVRV can indicate that the asset is potentially undervalued, often prompting accumulation by long-term investors.
HBAR Trading Activity and On-Chain DataHedera’s spot trading volume reached $154,901,395 over 24 hours, while derivatives activity was slightly higher at about $180 million for the same period. According to analytics provider SoSoValue, HBAR’s spot market turnover rate stands at 4.45% in that window. Although the long versus short ratio is currently marginally in favor of bullish traders at 1.069, the liquidation data paints a different picture.
Out of $430,500 in liquidated HBAR positions, $422,600 were from long positions, highlighting that short-sellers have recently gained momentum. They appear to be testing support near the $0.08 mark, with HBAR currently trading at $0.079. This price sits below the key SuperTrend resistance value of $0.096 and the $0.086 mid-range Bollinger Band.
MetricValueHBAR price (current)$0.079SuperTrend level$0.096Bollinger Band (mid)$0.086Spot trading volume (24h)$154,901,395Derivatives volume (24h)$180,000,000Long vs Short Ratio1.069Long liquidations (24h)$422,600Total liquidations (24h)$430,500ETF net inflow (12 months)+69%ETF asset value$113 millionHBAR yearly change-52%HBAR YTD change-28%Recovery to higher price levels could depend on renewed whale participation and further institutional buying. The lack of substantial inflows in recent weeks suggests that while conviction in the ETF remains, cautious positioning prevails.
A positive shift in trading activity and whale accumulation may be required if HBAR is to reclaim significant resistance points above $0.08 in the near term.
Howard Hughes Holdings (HHH) nahradí společnost Arcosa (ACA) v indexu S&P SmallCap 600 před zahájením obchodování dne 28. října 2026 poté, co společnost CRH dokončila akvizici společnosti Arcosa 23. října.
, /PRNewswire/ -- Howard Hughes Holdings Inc. (NYSE: HHH) will replace Arcosa Inc. (NYSE: ACA) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 28. S&P 500 constituent CRH plc (NYSE: CRH) has acquired Arcosa in a deal that closed today, October 23.
Following is a summary of the changes that will take place prior to the open of trading on the effective date:
Effective Date
Index Name
Action
Company Name
Ticker
GICS Sector
October 28, 2026
S&P SmallCap 600
Addition
Howard Hughes Holdings
HHH
Real Estate
October 28, 2026
S&P SmallCap 600
Deletion
Arcosa
ACA
Industrials
ABOUT S&P DOW JONES INDICES
S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.
S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spglobal.com/spdji/en/.
Santiment zaznamenal během jediného dne 2 295 nových adres UNI, což je nejvíce od listopadu 2022. Metrika měří první interakce s UNI, nikoli počet uživatelů.
TLDR: Santiment counted 2,295 new UNI addresses in one day, the highest network-growth reading since November 2022, based on first-time interactions with UNI. Santiment pointed to new Uniswap v4 features, expanded liquidity routing and continued Unichain development as possible reasons for the increase, without naming a single driver. Santiment identified $7 as the key downside level, $7.50 as the first meaningful reclaim and $8 as a possible retest if support and network activity remain firm. If UNI loses $7 while new address creation fades, Santiment said the spike may reflect short-term excitement rather than sustained adoption; follow-through will clarify the trend. UNI wallet creation reached 2,295 addresses in one day, its highest network growth reading since November 2022, Santiment said. The increase puts network activity near levels last seen four years ago, while UNI remains close to $7. Santiment linked the rise in participation to three factors:
Uniswap v4 features, liquidity routing and continued work on Unichain. The metric tracks new addresses that interact with UNI for the first time. It does not show how many people control those addresses or whether each will remain active. For traders, the wallet surge adds an adoption signal to the price levels in focus.
UNI Wallet Creation Reaches a Four-Year Network Growth Peak The UNI wallet creation count marks the strongest daily increase since November 2022. Santiment defines network growth by counting addresses that interact with UNI for the first time. The figure measures fresh on-chain participation, not a direct count of new customers. One person may control several wallets, while some addresses may see little activity after their first interaction. The data shows a jump in first-time address activity, but cannot confirm lasting adoption by itself.
Source: Santiment Santiment pointed to Uniswap v4 features, expanded liquidity routing and ongoing Unichain development as possible reasons for the increase. Together, these developments give users new ways to access the protocol and ecosystem. The post did not say which development contributed most, however. Nor does the one-day reading show that each new address arrived because of a specific product. The explanations remain plausible, while the increase in first-time addresses is the measured signal.
The next test is whether UNI wallet creation stays elevated. Santiment said readings above the recent baseline could strengthen the case for continued participation. If counts quickly fall back, the daily high may reflect short-term attention. Several days of elevated activity would offer stronger evidence that new addresses keep exploring UNI. Daily growth can fluctuate, so traders may seek follow-through before treating it as a lasting change.
UNI Price Levels Put $7 Support and $7.50 Reclaim in Focus UNI’s price structure centers on $7.00 and $7.50. Santiment called $7 the key downside level and $7.50 the first meaningful reclaim. These levels frame the immediate question: can buyers defend support, then recover initial resistance? Wallet growth adds context, but neither the network metric nor these levels guarantees a move. Confirmation depends on price response and continued activity.
If UNI holds above $7 while new address growth stays above its recent baseline, Santiment said a renewed test of $8 would be favored. That scenario pairs price stability with continuing participation. A reclaim of $7.50 is the first level to watch before any move toward $8. A push through $7.50 would show buyers recovering ground, but one brief move would not establish a breakout. Follow-through in both price and UNI wallet creation would strengthen the recovery case.
Source: TradingView If UNI falls below $7 as UNI wallet creation fades, Santiment said the spike could reflect short-term excitement rather than sustained adoption. If price slips under support while activity remains strong, the signals conflict. If activity fades but price holds, traders still need evidence that buyers will defend $7. Daily closes and new address counts may clarify which pattern is developing.
The two indicators answer different questions. Wallet counts show whether new addresses are beginning to interact with UNI, while price shows whether buyers are absorbing available supply. A rise in new addresses can coincide with a flat or falling token price when selling demand is stronger.
Společnost KB Home má ve čtvrtletí vykázat zisk na akcii 1,21 USD, což představuje meziroční pokles o 36,98 %, a tržby ve výši 1,53 miliardy USD, meziročně nižší o 9,81 %.
In the latest trading session, KB Home (KBH - Free Report) closed at $47.05, marking a +1.86% move from the previous day. The stock exceeded the S&P 500, which registered a loss of 0.52% for the day. Meanwhile, the Dow experienced a drop of 1.24%, and the technology-dominated Nasdaq saw a decrease of 0.21%.
The homebuilder's shares have seen a decrease of 3.06% over the last month, surpassing the Construction sector's loss of 6.53% and falling behind the S&P 500's loss of 1.21%.
The investment community will be paying close attention to the earnings performance of KB Home in its upcoming release. It is anticipated that the company will report an EPS of $1.21, marking a 36.98% fall compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $1.53 billion, indicating a 9.81% decrease compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $3.26 per share and revenue of $5.02 billion, which would represent changes of -50% and -19.55%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for KB Home. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.31% higher. KB Home presently features a Zacks Rank of #3 (Hold).
In terms of valuation, KB Home is currently trading at a Forward P/E ratio of 14.17. This represents a premium compared to its industry average Forward P/E of 13.01.
We can also see that KBH currently has a PEG ratio of 2.4. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Building Products - Home Builders was holding an average PEG ratio of 2.35 at yesterday's closing price.
The Building Products - Home Builders industry is part of the Construction sector. This industry currently has a Zacks Industry Rank of 234, which puts it in the bottom 5% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Securitize zpřístupnila na Solaně 12 tokenizovaných amerických akcií, včetně akcií společností Apple, Nvidia a Tesla, způsobilým investorům v USA, EU a dalších povolených jurisdikcích. Každý token je kryt jednou akcií, která není poskytována k zápůjčce.
Securitize has confirmed that 12 tokenized U.S. stocks, including Apple, Nvidia and Tesla, are live on Solana for eligible investors, with each token backed by a share the company says is never lent out.
Summary
12 stock tokens are live on Solana, including Apple, Nvidia, Tesla, Microsoft, and Amazon.
Securitize says backing shares are never lent out, and eligible U.S. investors can participate.
Holders receive security entitlements; direct registration requires conversion, subject to the available arrangements.
The original launch announcement dates to Oct. 8, before the latest posts confirming availability.
In its Oct. 23 X post, Securitize said that eligible investors in the United States, European Union and other permitted jurisdictions can trade the products through Securitize Stocks. Solana repeated the availability announcement, including the one-for-one backing and no-lending claims.
Securitize Stocks went live after an Oct. 8 announcement
Securitize’s original announcement named Apple, Microsoft, Nvidia, Alphabet, Tesla, Meta, Amazon, Netflix, Circle, SpaceX, Strategy, and Palantir in the initial offering. The latest promotional image displays the same companies, including Alphabet’s GOOGL ticker.
The company had announced the product on Oct. 8. Its Oct. 23 posts describe the stocks as available, without announcing a new set of 12 companies or a separate expansion in the number of products.
As crypto.news previously reported on Oct. 9, the stock entitlement structure gives holders an interest through an intermediary. Simply holding a token does not put the investor’s name on the underlying company’s shareholder register.
The earlier coverage identified eligibility and the precise underlying interest as questions for individual products, particularly SpaceX. Inclusion in a platform’s catalog does not by itself establish identical access conditions for every security or investor.
The Oct. 8 release named Jump Trading as a market maker supporting the initial Solana offering. It described transactions settling in USDC and identified Securitize Europe Brokerage and Markets, S.A. as the offering entity in the EU. Planned lending and collateral uses were described as future applications, including potential support through Aave.
Eligible US investors must complete onboarding
Securitize’s product page identifies Securitize Markets, LLC as the SEC-registered broker-dealer offering the stocks. The page says participation remains subject to onboarding, identity verification, and jurisdictional eligibility.
Investors can buy with USDC and hold the tokens in an approved Solana wallet, according to the product description. The page advertises trading 24 hours a day, five days a week, while describing seven-day trading as a future feature.
The platform says an underlying share is held in a segregated account for each tokenized stock. Its description includes dividend payments after applicable withholding and participation in shareholder votes.
Securitize’s disclosures state that the underlying issuers have neither sponsored nor endorsed the products. Investors hold security entitlements through the broker-dealer and become registered shareholders only if they convert.
The page warns that extended-hours trading carries additional risks. Its USDC disclosure states that the stablecoin is neither legal tender nor a bank deposit and has no FDIC or SIPC protection.
Kraken’s xStocks carry different access and ownership terms
Kraken’s tokenized stock vaults, introduced on Sep. 14, offered estimated net yields of 2% on SPYx and QQQx and 1.8% on NVDAx during the initial launch period. The products track two U.S.-listed funds and Nvidia shares.
Kraken said those tokens provide exposure to the referenced assets’ prices without the voting rights, dividend rights, or legal claims against the underlying companies associated with conventional share ownership. The vault service excluded residents of the United States, United Kingdom, Canada and Australia.
Its vault documentation described a three-day redemption process and risks including liquidation, smart-contract failures, liquidity shortages, bad debt and cross-chain transactions. Kraken warned that a stablecoin losing its peg or a custodian failing could reduce a user’s vault balance.
Separately, Payward’s Sep. 24 Ledger wallet partnership outlined hardware-wallet support for eligible xStocks customers. The companies planned deeper integration so users could buy, sell, and transfer tokens while holding their own keys.
Payward put cumulative xStocks transaction volume above $42 billion in that announcement. Its terms continued to exclude U.S. persons, and hardware-wallet support did not remove the jurisdictional restrictions. The September coverage distinguished holding tokens in a wallet from depositing them into a lending strategy.
Robinhood stock tokens use derivative contracts
Robinhood’s stock token terms describe its Classic Stock Tokens as derivative contracts under MiFID II. Holders receive exposure to a referenced asset’s price without owning the underlying shares or receiving voting rights, according to the company’s description.
Robinhood said the assets supporting those contracts were held through a U.S.-licensed institution. Its stock tokens remained unavailable to U.S. investors in the September coverage, despite referencing securities traded in American markets.
The same coverage reported approximately $44 million in Robinhood tokenized assets in a comparison that put Ondo at $857 million and xStocks at $487 million. Those figures described the assets in that comparison, rather than trading volume.
Securitize’s Oct. 8 release described possible future trading on NYSE and OKXICE venues, while its disclosures said neither venue had launched and access remained subject to approval and review. The company reserved the right to withdraw listings where needed or required.
Shiba Inu (SHIB), a popular meme-based cryptocurrency, continues to experience volatile market movements, with red numbers dominating most recent trading sessions. Despite these fluctuations, new exchange data indicates that sellers may still control the market in the near term.
Exchange Netflow on the RiseCryptoQuant, a blockchain analytics company, has reported that Shiba Inu’s exchange netflow posted a positive balance in the past 24 hours. The netflow surged to over 77 billion SHIB, reflecting an increase of nearly 4% during the period.
This spike indicates that a substantial volume of SHIB tokens has been transferred to exchanges, making them available for sale. As of October 23, the net balance reached 77,298,600,000 SHIB, suggesting that more tokens are flowing into trading platforms than being withdrawn for holding or long-term investment.
Such positive netflow trends are generally interpreted as signs of mounting selling pressure, since rising balances on exchanges can signal that holders are preparing to liquidate their assets.
CryptoQuant reported that the increase in SHIB exchange netflow means the number of tokens sent to exchanges for potential sale far exceeds those being removed, pointing to a possible continuation of bearish sentiment.
The exchange netflow metric is watched closely by traders, as it often correlates with shifts in market sentiment and can foreshadow short-term price movements.
Mini dictionary: Exchange netflow – This metric measures the difference between the amount of a cryptocurrency sent to exchanges (inflow) and the amount withdrawn from exchanges (outflow) over a set period. A positive netflow indicates more tokens moving into exchanges, often interpreted as increased selling pressure, while a negative netflow usually points to accumulation or holding trends.
MetricLast 24 hoursImplicationSHIB exchange netflow+77,298,600,000 SHIBIndicates potential selling pressurePrice movementLocal high near $0.0000051Short-term price recoveryMarket Response and Price ActionDespite increased selling pressure, Shiba Inu’s price reversed its short-term trend and moved into positive territory, reclaiming a local peak around $0.0000051. This shift brought some relief to investors, as a burst of buying temporarily offset earlier losses.
Market watchers noted that this brief upward movement could signal the potential for bullish traders to regain control if new demand materializes.
While Shiba Inu’s netflow data points to persistent selling, the recent price bounce has offered hope to participants who believe momentum could soon shift in favor of buyers.
The dynamic between exchange activity and price movement underscores the ongoing uncertainty in the meme coin segment, where rapid sentiment shifts frequently drive sudden volatility.
Akcie Petrobras (PBR) při posledním uzavření vzrostly o 2,34 % na 26,22 USD; před zveřejněním hospodářských výsledků se očekává meziroční růst EPS o 47,56 %.
In the latest close session, Petrobras (PBR - Free Report) was up +2.34% at $26.22. The stock exceeded the S&P 500, which registered a loss of 0.52% for the day. Elsewhere, the Dow saw a downswing of 1.24%, while the tech-heavy Nasdaq depreciated by 0.21%.
Prior to today's trading, shares of the oil and gas company had gained 22.94% outpaced the Oils-Energy sector's gain of 5.63% and the S&P 500's loss of 1.21%.
Investors will be eagerly watching for the performance of Petrobras in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 10, 2026. It is anticipated that the company will report an EPS of $1.21, marking a 47.56% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $31.84 billion, reflecting a 35.62% rise from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $5.99 per share and revenue of $120.93 billion, indicating changes of +113.93% and +35.58%, respectively, compared to the previous year.
It is also important to note the recent changes to analyst estimates for Petrobras. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 24.53% upward. Petrobras presently features a Zacks Rank of #3 (Hold).
In terms of valuation, Petrobras is currently trading at a Forward P/E ratio of 4.28. Its industry sports an average Forward P/E of 7.69, so one might conclude that Petrobras is trading at a discount comparatively.
Also, we should mention that PBR has a PEG ratio of 2.29. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As of the close of trade yesterday, the Oil and Gas - Integrated - International industry held an average PEG ratio of 0.7.
The Oil and Gas - Integrated - International industry is part of the Oils-Energy sector. This industry currently has a Zacks Industry Rank of 17, which puts it in the top 7% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Phillip Securities zvýšila doporučení pro SpaceX z „prodat“ na „koupit“ a ztrojnásobila cílovou cenu na 250 USD poté, co tržby divize SI vzrostly na 7,6 miliardy USD.
SPCX Space Exploration Technologies$147.49+$2.74 (+1.89%)
NASDAQ · As of 4:00 PM ET 10/23/26
Space Exploration Technologies (SPCX +1.89%), better known as SpaceX, a launch services, satellite broadband, and space infrastructure provider, closed at $147.49, up 1.89%. Premarket analyst upgrades and regular-session coverage of tower-lease talks helped keep investors focused on growth and mobile ambitions.
Trading volume reached 109.4 million shares, coming in nearly 1% above its three-month average of 99.4 million shares. Space Exploration Technologies IPO'd in 2026 and has fallen 8% since going public.
How the markets moved todayThe S&P 500 (^GSPC -0.52%) fell 0.52% to 7,623, while the Nasdaq Composite (^IXIC -0.21%) slipped 0.21% to 25,955. In aerospace, defense, and satellite communications, Rocket Lab (RKLB +2.69%) closed at $52.60, up 2.69%, and AST SpaceMobile (ASTS +2.63%) finished at $39.79, up 2.63%, as space-linked peers drew steady attention.
What this means for investorsOn Friday, Oct. 23, SpaceX captured a rare double upgrade from Wall Street. Phillip Securities analyst Glenn Thum upgraded shares from Sell to Buy, bypassing Hold entirely. He also tripled the price target from $75 to $250 per share, implying an impressive upside potential of over 70% from its recent trading levels.
The dramatic reversal from bear to bull was driven by SpaceX's blowout third-quarter earnings report, which highlighted the spectacular growth of the company's artificial intelligence division, called Super Intelligence (SI).
SpaceX's SI business hit sales of $7.6 billion in Q3, up from $813 million last year, helping to grow total revenue 161% year over year to $14.6 billion. CEO Elon Musk stated the company's annual recurring revenue could reach a range between $500 billion and $1 trillion by the end of 2027. SI's success contributed to the bullish sentiment from Phillip Securities.
SI isn't the only factor galvanizing shares. SpaceX is reportedly negotiating tower leases as it seeks at least 80,000 U.S. cell sites in a bid to broaden its wireless mobile addressable market. The news of intensifying carrier competition caused telecom stocks to drop.
SpaceX ve třetím čtvrtletí zvýšila tržby z umělé inteligence meziročně o 830 % na 7,56 miliardy USD a stala se silným konkurentem CoreWeave v segmentu neocloudu.
CoreWeave stock has been under pressure lately. Investors are concerned about the company's heavy debt load, plans for additional large capital expenditures to continue building out its artificial intelligence (AI) data center footprint, and surging interest expenses.
Making matters worse, the company is facing ramping competition in the neocloud space. Space Exploration Technologies (SPCX +1.89%) built its name around its reusable rocket technologies, orbital launch services, and its Starlink satellite communications network, but the company is also rapidly scaling its neocloud business. That could create additional pressures for CoreWeave.
Image source: Getty Images.
SpaceX has rapidly become a neocloud leader
SpaceX's recently published third-quarter report showed that sales for its artificial intelligence businesses surged 830% higher year over year to reach $7.56 billion. Meanwhile, its space segment's sales increased 6% to $1.77 billion, and its connectivity segment grew revenue by 69% to $5.25 billion. In other words, the company's AI businesses now generate more money than its space and connectivity segments combined.
SpaceX's AI revenue includes contributions from Grok and other sources, but the large majority of its segment sales in the quarter likely came from renting out compute to customers.
For comparison, CoreWeave posted revenue of roughly $2.58 billion. The company will likely see a substantial sequential quarterly sales increase, but SpaceX's neocloud business is likely generating substantially more revenue.
Extremely high demand means neocloud providers currently enjoy very strong pricing power, but that doesn't mean the space is immune to competitive dynamics. As the emerging powerhouse in the neocloud space, SpaceX has strong positioning that could eventually pressure CoreWeave. SpaceX also has much more solid financial footing, potentially giving it the ability to explore pricing options that would prove seriously problematic for CoreWeave.
SPCX Space Exploration Technologies$147.49+$2.74 (+1.89%)
NASDAQ · As of 4:00 PM ET 10/23/26
SpaceX's rise could make it harder for CoreWeave to secure the level of access to next-generation processors it wants from Nvidia. On the one hand, Nvidia's substantial stake in CoreWeave suggests that the neocloud specialist will remain a preferred customer. On the other hand, Nvidia actually holds a substantially larger position in SpaceX.
That doesn't necessarily mean Nvidia would deprioritize CoreWeave or divest its stock, but the graphics processing unit (GPU) leader also famously isn't wed to its investment positions -- having completely exited holdings in companies including Applied Digital and SoundHound AI in high-profile moves. If Nvidia finds itself weighing the significance of its relationship with CoreWeave against that with SpaceX, it's hard to imagine many scenarios in which the former comes out on top.
SpaceX's rise in the neocloud space doesn't necessarily mean CoreWeave is doomed, but it could create additional stress points that complicate the scaling and GPU lifecycle models used to suggest strong opportunities, despite the business's large debt load.
Cloudová kapacita AWS je z velké části vyprodaná až do roku 2027 a významná část kapacity je již vyprodaná i na rok 2028, uvedl šéf Amazonu Andy Jassy. Poptávku táhne infrastruktura pro AI.
Amazon (AMZN.O) CEO Andy Jassy said on Friday that Amazon Web Services' cloud computing capacity is largely sold out through 2027, with significant commitments extending into 2028, on growing demand for AI infrastructure.
In a video podcast with Andreessen Horowitz co-founder Ben Horowitz and general partner Erik Torenberg, Jassy said Amazon is struggling to keep pace with the insatiable demand from AI labs and enterprises.
Earlier this year, Amazon had said it would spend about $220 billion in capital expenditure for 2026
Jassy said the company "could invest a lot more and it wouldn't be a bad use of capital," considering cloud-computing capacity for 2026 is already sold out
"2027 is largely sold out. We always leave a certain amount for on demand and our inference service bedrock, or EC2, but largely sold out all the big chunks. A good chunk of 2028 is sold out," he said
EC2 is an AWS service that provides cloud servers for running applications, while Bedrock gives customers access to AI models to build generative AI applications
Amazon is scheduled to report third quarter results on October 29
AT&T (T -7.96%), a wireless and fiber telecom services provider, closed at $20.93, down 7.96%. Bloomberg's report on SpaceX's cell-site talks pressured the stock, and investors are now watching wireless competition and capital strategy.
Trading volume reached 84.6M shares, coming in about 88% above its three-month average of 45.1M shares.
How the markets moved todayS&P 500 (^GSPC -0.52%) fell 0.53% to 7,623, and the Nasdaq Composite (^IXIC -0.21%) slipped 0.21% to 25,955. In U.S. wireless telecommunications services and fiber broadband, Verizon Communications closed at $44.66, down 1.19%, while T-Mobile US fell 7.71% to $146.54 as concerns about carrier competition remained in focus.
What this means for investorsAT&T stock plunged after Bloomberg reported that Space Exploration Technologies is in negotiations to obtain access to around 80,000 cell sites, presumably to build America's fourth nationwide wireless network.
AT&T and its peers, Verizon and T-Mobile, have long operated on the premise that prospective new competitors would avoid entering the market due to the high likelihood of massive capital costs and low profit margins.
Now, SpaceX is blowing this theory out of the water. Additionally, with satellite coverage supplementing a terrestrial network, it would have a competitive advantage among customers who spend a lot of time in rural areas, likely placing further competitive pressure on AT&T.
T AT&T$20.93-$1.81 (-7.96%)
NYSE · As of 4:00 PM ET 10/23/26
These fears have also seemed to overshadow good news for AT&T. In its Oct. 21 earnings report, AT&T beat earnings estimates and raised its 2026 guidance. Additionally, NBT Bancorp bought 91,368 AT&T shares valued at around $2.23 million.
Admittedly, an added competitive challenge does not bode particularly well for AT&T. Nonetheless, AT&T provides a necessary service, and wireless customers tend to be sticky. Moreover, investors can buy AT&T stock now at an 11 P/E ratio and earn a 5.3% dividend yield, suggesting the Friday sell-off of the communication stock might be a buying opportunity.
BlackRock Canada ukončí fond iShares Convertible Bond Index ETF (CVD) přibližně 21. ledna 2027; obchodování na burze TSX má skončit přibližně 18. ledna.
TORONTO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (“BlackRock”) (NYSE:BLK) announced today that it intends to terminate iShares Convertible Bond Index ETF (the “Terminating Fund”), based on an ongoing process to review its product lineup. The Terminating Fund will terminate on or about January 21, 2027 (the “Termination Date”).
Terminating Fund NameTickeriShares Convertible Bond Index ETFCVD
BlackRock Canada expects that the units of the Terminating Fund will cease trading on the Toronto Stock Exchange (the “TSX”) and be voluntarily delisted from the TSX on or about January 18, 2027. In connection with the termination of the Terminating Fund, the distribution reinvestment plan, pre-authorized cash contribution plan and the systematic withdrawal plan of the Terminating Fund will be terminated on or about November 23, 2026.
The final monthly distribution is expected to be declared on or about December 21, 2026 and be paid on or about January 5, 2027.
In connection with the termination, the assets of the Terminating Fund will be liquidated. BlackRock Canada expects that the Terminating Fund's portfolio assets may mature or be sold for cash in advance of the Termination Date, resulting in the Terminating Fund deviating from its investment objectives and strategies in a manner consistent with liquidation. As soon as practicable following the Termination Date, the liquidation proceeds will be distributed, after paying or providing for all liabilities and obligations of the Terminating Fund, pro rata among unitholders of record of the Terminating Fund on the Termination Date. Following the termination and distributions described above, the Terminating Fund will be dissolved. BlackRock Canada will issue an additional press release on or about the Termination Date confirming final details of the termination.
About BlackRock
BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate.
About iShares
iShares unlocks opportunity across markets to meet the evolving needs of investors. With more than twenty-five years of experience, a global line-up of more than 1,800 exchange traded funds (ETFs) and US$6.4 trillion in assets under management as of September 30, 2026, iShares continues to drive progress for the financial industry. iShares funds are powered by the expert portfolio and risk management of BlackRock.
iShares® ETFs are managed by BlackRock Asset Management Canada Limited.
Commissions, trailing commissions, management fees and expenses all may be associated with investing in iShares ETFs. Please read the relevant prospectus before investing. The funds are not guaranteed, their values change frequently and past performance may not be repeated. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional.
Shares of membership-based warehouse retailer Costco Wholesale (COST -1.46%) trade near $1,010 as I write, nearly 8% under the record close of $1,094.32 they set on May 19.
The company behind the stock keeps delivering. Costco's earnings per share grew 14% in fiscal 2026 (the 52 weeks ending Aug. 30, 2026), faster than the 10% increase a year earlier. And net sales climbed 10% to around $297 billion.
What might $5,000 put in the stock now be worth by the end of 2030?
With a forecast based on earnings growth, a lower valuation multiple, and the dividend, I get around $6,350. It's a decent gain. But the same $5,000 in an index fund matching the long-term average of the S&P 500 (^GSPC -0.52%) might reach around $7,450.
Image source: Getty Images.
How fast can earnings grow?Costco's fiscal 2026 earnings included a one-time boost of $0.15 a share from tariff refunds in the fiscal fourth quarter. Without that, the company earned around $20.61 a share, still about 13% above fiscal 2025's $18.21.
Earnings per share were $11.27 in fiscal 2021, so this rate matches their average growth of around 13% a year for the last five years.
But the next few years likely won't match it. Costco hiked its yearly membership fees in the U.S. and Canada on Sept. 1, 2024, and it records that income gradually over each member's year. The higher fees made up around 30% of the 11% growth in membership fee revenue in fiscal 2026, according to Costco's annual report. By the fiscal fourth quarter, membership fee income was up only about 7% year over year.
That matters because membership fees brought in around $5.9 billion last fiscal year, or about half of Costco's $11.7 billion in operating income.
The rest of the business still has room to grow, of course. Comparable sales excluding gas prices and foreign exchange climbed 6.6% in fiscal 2026, and Costco plans to open up to 33 warehouses in fiscal 2027, including five relocations.
I'll assume earnings per share grow around 11% a year from here, a step down from the last five years but still a solid rate. That puts fiscal 2030 earnings per share at about $31.30.
Costco's valuation might come downThe price investors pay for these earnings arguably counts just as much. At around $1,010, Costco stock trades at about 49 times fiscal 2026 earnings. At the end of fiscal 2023, the stock fetched about 38 times that year's earnings of $14.16 per share.
I'll assume the price-to-earnings ratio lands at 40 times earnings by the end of 2030. That's still a premium price for a retailer, and I think it's fair for a business growing earnings roughly 11% a year.
At 40 times fiscal 2030 earnings of about $31.30, Costco stock would trade near $1,250. Now, $5,000 gets about 4.95 shares, so the stake might be worth around $6,190.
Costco also pays a dividend of $1.47 per share a quarter, after lifting it 13% in April. If the payout keeps climbing around 11% a year, in line with earnings, the 4.95 shares might collect a bit over $150 in regular dividends by the end of 2030 (I'm not counting any special dividends). That takes the total to around $6,350, a gain of about 6% a year.
COST Costco Wholesale$1,003.32-$14.89 (-1.46%)
NASDAQ · As of 4:00 PM ET 10/23/26
An index fund might do betterWith dividends, the S&P 500 has returned about 10% a year since 1928. At that rate, $5,000 put in the index through a fund on Oct. 23 could rise to about $7,450 by the end of 2030 -- about $1,100 more than my Costco forecast.
Then again, the market could return less than its long-run average in the next few years. And Costco's price-to-earnings ratio may not come down at all. The stock closed each of the last three fiscal years at more than 45 times earnings. But for Costco to keep up with the index fund, it'd have to trade at about 47 times earnings at the end of 2030, near where it trades today, while still growing earnings 11% a year.
Put another way, the company might do everything I'm assuming, and the stock could still trail the market if investors pay a bit less for every dollar Costco earns.
I think the warehouse club is still one of the best retailers to own for the long run, and I'd be comfortable adding shares slowly over time. But I wouldn't expect the stock to beat an index fund from here.
Circle ukončila nové emise USDC na Noble; Cosmos přechází na USDC vydávané společností Injective. Limity pro spalování v rámci CCTP V1 se začnou snižovat 31. října.
Circle is winding down USDC on Noble, and Cosmos is adopting Injective-issued USDC. Key dates: October 31 burn limits shrink, January 12, 2027 contract pause.
Circle has stopped minting new USDC on Noble, the chain that has issued the stablecoin for the Cosmos ecosystem, and the first deadline for holders arrives next week. Cosmos is shifting to a version of USDC issued on Injective, the chain behind $INJ.
What changes on October 31 and January 12According to Coinpaprika, Circle disabled new USDC minting on Noble on October 13, 2026, and will pause the Noble USDC contract on January 12, 2027. The staged timeline has burn limits shrinking from October 31, and exit routes narrowing after December 1.
The October 31 date matters because it affects the older transfer system. Blockonomi reports that CCTP V1 burn limits on Noble start shrinking on that date and reach zero on a rolling basis as the January deadline approaches. CCTP is Circle's Cross-Chain Transfer Protocol.
The reason is technical. Circle is moving to CCTP V2, and Noble will not receive it, according to Coinpaprika. The change ends USDC's legacy infrastructure on Noble rather than a withdrawal from Cosmos. Noble itself is not shutting down, edgeX notes.
Injective USDC becomes the Cosmos standardCrypto Briefing reports that Cosmos Hub, dYdX and the routing layer Skip:Go have signed on, making Injective USDC the canonical stablecoin standard across chains that previously relied on Noble for issuance.
Holders can swap Noble USDC, now displayed as USDC.n, for Injective-issued USDC, or USDC.inj, through Skip:Go. CryptoSlate reported that migration opened on September 11. The same report put the affected amount at roughly $92 million in USDC. DeFiLlama data cited by edgeX showed about 91.6 million USDC circulating on Noble as of September 11.
Holders who miss the deadlines still have a backstop, but it is narrower. Circle plans to take a snapshot of remaining balances on January 12 and open manual redemption the next day. BitRss, republishing CryptoSlate, said eligibility requires the USDC to be in a wallet controlled by the user and that holders pass Circle's compliance and security checks. USDC left in liquidity pools or smart contracts at the snapshot will not qualify, so protocol-level migration is more urgent than the January date suggests.
Cosmos Labs has urged holders to migrate before October 31 rather than wait for January, Coinpaprika reports.
SourcesCoinpaprika: Circle Pulls USDC From Noble, Forcing Cosmos Onto Injective
CryptoSlate: Circle's Noble shutdown leaves Cosmos racing to move $92 million in USDC
Crypto Briefing: Injective USDC becomes canonical USDC standard across Cosmos
In the latest trading session, Intuit (INTU - Free Report) closed at $343.39, marking a -3.24% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.52%. Meanwhile, the Dow experienced a drop of 1.24%, and the technology-dominated Nasdaq saw a decrease of 0.21%.
The stock of maker of TurboTax, QuickBooks and other accounting software has risen by 28.06% in the past month, leading the Computer and Technology sector's loss of 7.7% and the S&P 500's loss of 1.21%.
Analysts and investors alike will be keeping a close eye on the performance of Intuit in its upcoming earnings disclosure. The company is expected to report EPS of $2.47, down 26.05% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $4.3 billion, up 10.81% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of $23.5 per share and a revenue of $23.39 billion, demonstrating changes of -3.17% and +9.07%, respectively, from the preceding year.
Investors might also notice recent changes to analyst estimates for Intuit. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.03% upward. Intuit is currently sporting a Zacks Rank of #2 (Buy).
In terms of valuation, Intuit is currently trading at a Forward P/E ratio of 15.1. For comparison, its industry has an average Forward P/E of 17.66, which means Intuit is trading at a discount to the group.
Also, we should mention that INTU has a PEG ratio of 1.15. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Computer - Software industry was having an average PEG ratio of 1.49.
The Computer - Software industry is part of the Computer and Technology sector. This industry, currently bearing a Zacks Industry Rank of 55, finds itself in the top 23% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow INTU in the coming trading sessions, be sure to utilize Zacks.com.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Průzkum společnosti Mizuho ukázal, že 94 % z více než 600 aktivních uživatelů Robinhood by obchodovalo perpetuální futures kontrakty na jednotlivé akcie, pokud by je platforma zavedla.
Robinhood (HOOD -1.56%) hasn't announced any plans to launch single-stock perpetual futures on its platform yet, but there seems to be a lot of pent-up demand for them. In a recent Mizuho (MFG -1.44%) survey of over 600 active Robinhood users, 94% of respondents were willing to trade single-stock perpetual futures if they became available. Let's see why that could be bullish for Robinhood's stock -- which has declined nearly 30% over the past 12 months.
In traditional investing, investors can buy options to either buy a stock (a call) or sell it (a put) at a fixed strike price with a set expiration date. As an option approaches its expiration date, its value declines because there is less time remaining for the stock to make a major move.
Image source: Getty Images.
Single-stock perpetual futures are similar to calls and puts, but they don't have strike prices or expiration dates. Instead, an investor simply takes a bullish or bearish position in a stock, deposits cash as collateral, and chooses a leverage ratio that multiplies their gains or losses.
For example, depositing $200 at 5x leverage gives you $1,000 of exposure to an underlying stock. If that stock starts trading at $100 and rises by $10, your $1,000 position grows to $1,100 -- giving you a $100 profit on your $200 deposit. If it drops 10% to $90, it shrinks to $900 -- resulting in a $100 loss. If the stock drops near $80, the platform automatically liquidates the entire position before it consumes your entire $200 deposit.
To keep the contract's price tethered to the actual stock price without fixed strike prices or expiration dates, the buyers and sellers pay each other small funding fees. When buyers push the contract's price above the actual stock, the longs pay the shorts a periodic fee; when selling pressure pushes it lower, the shorts pay the longs a periodic fee.
HOOD Robinhood Markets$95.07-$1.51 (-1.56%)
NASDAQ · As of 4:00 PM ET 10/23/26
Why could this be bullish for Robinhood?
Robinhood already launched perpetual futures for cryptocurrencies in the U.S. and Europe this year, so it seems like a natural move to launch them for individual stocks as well. It would also complement its forward-thinking strategy of entering new markets -- including tokenized real-world assets (RWAs) and prediction markets -- before traditional brokerages.
Robinhood's stock slumped over the past year as rising interest rates and Treasury yields curbed the market's appetite for riskier investments. But many of its funded customers -- which grew 7% year over year to 28.4 million in the second quarter of 2026 -- could still be interested in using single-stock perpetual futures to trade some more volatile stocks with less capital. Therefore, expanding into that nascent market could be a bullish sign for Robinhood's stock.
Pár USD/JPY během posledních dvou obchodních seancí klesl téměř o 1 %; jen podporuje inflace v Japonsku ve výši 2,1 % a očekávání přísnější měnové politiky Bank of Japan.
As the trading week comes to an end, one of the most relevant developments in the FX market has been the renewed strength of the Japanese yen. This can be seen in the recent performance of USD/JPY, which has fallen nearly 1.0% over the last two trading sessions, highlighting a meaningful recovery in the Japanese currency against the U.S. dollar.
For now, the selling pressure observed around the pair is being driven primarily by the loss of momentum in U.S. Treasury yields. This has been reinforced by Japan's latest inflation data, released toward the end of the week, which has started to strengthen expectations of a potentially more aggressive Bank of Japan in the coming months. As a result, the yen has managed to recover part of the ground lost in previous months and, as long as these catalysts continue to support the Japanese currency, selling pressure around USD/JPY could remain relevant in the sessions ahead.
Is the Dollar Beginning to Lose Strength?
A loss of momentum around the U.S. dollar became increasingly evident throughout the week. Part of this dynamic has been driven by the moderation observed in 10-year U.S. Treasury yields, which temporarily moved below the 5.0% area.
This development is important because lower yields reduce part of the relative attractiveness of dollar-denominated investments. As a result, demand for the U.S. currency may also begin to soften in the short term.
The impact has already started to become visible in the behavior of the DXY, the index that measures the strength of the dollar against its main peers. In recent sessions, the index has retreated consistently, moving away from its yearly highs and currently trading near the 102-point area. This decline suggests that demand for the dollar has begun to moderate after several weeks of relatively solid strength, a dynamic that appears closely linked to the loss of momentum in the U.S. bond market.
Source: TradingEconomics
This behavior is particularly relevant because, as part of the relative advantage of holding dollar-denominated assets begins to fade, other currencies such as the yen have started to recover ground. In fact, the recent strength observed in the Japanese currency appears closely tied to this loss of relative attractiveness within U.S. financial markets.
As long as Treasury yields continue moving within a moderation phase, the yen could continue recovering part of the ground lost throughout much of 2026. Under this scenario, selling pressure around USD/JPY may remain an important factor influencing the pair in the short term.
Do Japan's Inflation Data Matter?
In addition to the weakness observed in the dollar, investors have also been paying close attention to Japan's latest inflation release. Annual inflation rose to 2.1%, reaching its highest level of 2026 and maintaining a relatively consistent upward trend over recent months.
This remains important because inflation is now developing slightly above the 2.0% target established by the Bank of Japan, a situation that could start generating greater concerns about inflationary pressures within the Japanese economy.
Source: TradingEconomics
The data have also started to influence monetary policy expectations. Only a few weeks ago, markets were pricing more than a 90% probability that the Bank of Japan would leave its policy rate unchanged at 1.25% during the October 28 meeting. However, by the end of the week that probability had fallen toward 80% area.
At the same time, expectations for the December meeting now imply close to a 60% probability that interest rates could rise to 1.50%.
Source: Centralbankwatch
This suggests markets are increasingly positioning for a more aggressive Bank of Japan over the coming months. Although Japanese rates remain relatively low compared to the current 4.0% reference rate in the United States, it is important to remember that Japan has maintained exceptionally low rates for decades.
For this reason, any gradual shift toward a more restrictive monetary policy stance could begin to alter investor perceptions regarding yen-denominated assets. If this process continues, the interest-rate differential between Japan and other major economies could gradually narrow, eventually becoming a meaningful catalyst for demand for the Japanese currency.
As a result, if the Bank of Japan continues moving toward a more aggressive stance than markets have been accustomed to over recent years, selling pressure around USD/JPY could remain an important theme even beyond the short term.
USD/JPY Technical Forecast
Source: StoneX, Tradingview
The bearish bias is becoming relevant once again: Although USD/JPY had recently entered a phase of short-term neutrality after partially breaking the bearish trendline developed over previous months, recent price action has once again given prominence to selling pressure. As a result, the broader bearish structure is regaining relevance within the daily chart. As long as price continues approaching key support zones, the long-standing bearish trendline could once again become the dominant technical structure during the weeks ahead.
MACD: The MACD histogram continues to trade slightly below the 0 neutral line, a reading that reflects weakening momentum within short-term moving averages. If this dynamic remains intact, it could continue supporting a more established bearish bias in the sessions ahead.
RSI: A similar picture can be observed in the RSI, whose line remains below the 50 neutral level. This suggests that selling momentum has started to regain traction and supports the possibility that the bearish bias could remain relevant in the short term.
Key Levels:
158.86 – Key Resistance: A level that aligns with the 200-period simple moving average and represents the most important upside barrier in the short term. A sustained move above this reference could significantly alter the current technical structure and open the door to a more consistent bullish trend over the coming weeks.
157.38 – Near-Term Barrier: A level that coincides with the base of the recent consolidation range and also develops near the 50-period simple moving average. This could become the main level to monitor in the event of short-term bullish corrections.
155.30 – Key Support: A support zone established during previous weeks that remains one of the most important downside barriers on the chart. Price action returning toward this level could restore the dominance of selling pressure and reinforce the relevance of the broader bearish trendline as the market's primary technical structure over the coming weeks.
Written by Julian Pineda, CFA, CMT – Market Analyst
Aptos na mainnetu spustil tři volitelné vrstvy soukromí: Keyless Accounts, Confidential APT a šifrovaný fond transakcí (mempool) k ochraně identity, částek a transakčních záměrů.
Public blockchains have always had an awkward relationship with privacy. Every transfer, balance and pending trade sits in the open, like a bank statement taped to a lamppost.
Aptos is trying to fix that without tearing down the lamppost. The network has rolled out three opt-in confidentiality layers on mainnet, covering who you are, how much you send and what you intend to do before your transaction lands.
The three features are Keyless Accounts, Confidential APT and an Encrypted Mempool. Together they were announced on October 13, 2026, and they mostly reach users through the Petra Wallet and related tools.
Three layers, three different problems
Layer one: identity. Keyless Accounts let people create a wallet using Google or Apple credentials. The point is that users can manage an identity on-chain without that identity being directly tied to their blockchain address.
Layer two: amounts. Confidential APT encrypts balances and transfer amounts using zero-knowledge proofs. Addresses stay visible, so the network can still verify that a transfer happened between two parties.
Layer three: intent. The Encrypted Mempool keeps transaction payloads encrypted until they are finalized into blocks. The goal is to blunt miner extractable value, better known as MEV.
The fine print
Privacy on Aptos does not come free. Encrypted transactions require a minimum gas price that is double the network’s base minimum.
There is also a compatibility gap. Certain account types, including Keyless Accounts, cannot currently sign encrypted transactions.
Every layer is opt-in. Nobody is forced into encryption, and the default experience on Aptos remains transparent.
How Aptos got here
The rollout follows a string of governance proposals. Confidential APT received approval in April 2026 and began drawing real usage afterward.
By mid-August 2026, approximately 15,000 APT had been moved into confidential pools.
Aptos itself launched in 2022. It is built on the Move programming language and uses Block-STM parallel execution, an approach designed to process many transactions at once rather than strictly one after another.
Petra, the wallet doing much of the distribution work here, already bundles a lot under one roof. It supports buying, swapping and sending assets, native APT staking, Ledger hardware wallet connections, Google and Apple social log-ins, and perpetual futures trading inside the wallet.
What this means
The most interesting design choice is what Aptos chose not to hide. Addresses remain visible under Confidential APT, which keeps a trail that auditors and compliance teams can still follow.
The use cases the network is targeting reflect that balance. Private payments and treasury operations are on the list, along with compliance pathways for participants who need them.
The doubled gas floor sets up a simple calculation for active traders. If the cost of being front-run regularly exceeds the extra fee, the encrypted route pays for itself.
The Keyless signing limitation is worth tracking. Until Keyless Accounts can sign encrypted transactions, the network’s friendliest entry point and its strongest trading protection live in separate lanes.
Disclosure: This article was edited by Estefano Gomez. For more information on how we create and review content, see our Editorial Policy.
Hershey’s is trying to win over health-conscious consumers with a new protein powder — and figure out how to get people on weight-loss drugs snacking again.
The 132-year-old candy company is working to entice consumers who have soured on sweets with a protein powder coming out in January.
With shares recently hitting a 52-week low, Hershey’s CEO Kirk Tanner has reportedly been talking one-on-one with consumers about weight loss drugs and snacks.
A woman administers a GLP-1 subcutaneous injection into her stomach tissue for weight management, obesity, or diabetes care. Matt Fowler KC – stock.adobe.com “They still love the products they love,” he told Bloomberg in an article published Friday. “They’re just eating less of them.”
With nearly 30% of obese adults in the US expected to be on appetite-suppressing GLP-1 drugs by 2035, Tanner wants to know how the company can innovate.
He pointed to rival Mars as an example.
“Today’s consumer wants new products and Mars has been delivering,” Tanner told Bloomberg.
The biggest “Payday” for Hershey’s might come from its venture into protein powder.
It partnered with protein-powder company VitaKey on the project. Details remain scarce.
A mound of Hershey’s chocolate bars. Faina Gurevich – stock.adobe.com Since Tanner came to Hershey last year, he’s upped research and development spending by 25%, with the goal of pumping out “Good & Plenty” ideas, according to Bloomberg.
Hershey’s is also expanding its gum-and-mints division to accommodate consumers battling “Ozempic breath” – the bad-breath side effect of the pound-shedding drug. Bloomberg reported gum sales at the company went up 8% earlier this year.
Hershey’s – which makes Skinny Pop, Dots Pretzels, and Pirate’s Booty – is looking to increase its savory offerings and is working on portion-controlled packaging.
The protein snack bar market has been bursting at the wrapper — it’s expected to go from $21.94 billion to $32.66 billion by 2031, an 8.2% growth rate. Rxbar, the company behind the popular golden ticket-wrapped David bars, hit a $2.25 billion valuation this year, in the biggest deal of the year in the industry, according to Forbes.
GLP-1s have posed challenges throughout the food business. Food giant Conagra has been scouring consumers’ credit-card data, social media posts and fast food orders to try to figure out what people still want to eat, according to the Wall Street Journal.
Grocery delivery giant Instacart has held preliminary discussions with Uber and DoorDash about a potential sale, The Information reported Friday.
An investment bank is helping Instacart, which is worth about $13 billion, assess its options, according to the report, which cited people familiar with the matter.
A takeover could fetch roughly $16 billion to $17 billion if a buyer pays a 30% to 40% premium, an estimate based on recent public tech deals.
Instacart, which was valued at $39 billion during the pandemic, is exploring a sale at a time when its market value stands at roughly $12 billion. REUTERS The potential sale comes as Uber and DoorDash expand their grocery delivery businesses and pursue multibillion-dollar acquisitions across the food delivery industry.
An Instacart spokesperson declined to comment when reached by The Post.
A takeover by either company could face antitrust scrutiny because of its competing grocery delivery operations.
Antitrust concerns helped derail DoorDash’s 2021 discussions to acquire Instacart at a valuation of $40 billion to $50 billion, The Information previously reported.
The discussions broke down partly over concerns about securing regulatory approval during the Biden administration, according to the report.
Instacart struck a deal with Uber in 2024 to offer restaurant delivery powered by Uber Eats through its grocery app.
Last year, Uber began using Instacart’s Carrot Ads technology to offer sponsored grocery placements on Uber Eats.
DoorDash previously held talks to acquire Instacart in 2021, but the discussions collapsed partly over antitrust concerns. Mojahid Mottakin – stock.adobe.com Earlier discussions between Uber and Instacart failed to advance as Uber pursued other acquisitions, The Information reported.
Instacart’s expansion into advertising has yet to close the revenue growth gap with Uber and DoorDash.
Instacart was valued at $39 billion in a 2021 private funding round amid a pandemic-era boom in grocery delivery.
By the time the company went public in 2023, its valuation had tumbled to roughly $10 billion.
Instacart shares have gained roughly 70% since the IPO. Its revenue growth slowed from 19% in 2023 to 11% in each of the following two years.
Uber, which has a market value of roughly $135 billion, is among the potential buyers that have held preliminary discussions with Instacart, according to The Information. ink drop – stock.adobe.com Instacart generated $480 million in free cash flow during the second quarter, while revenue increased 14% from a year earlier to just over $1 billion.
The company has said it plans to devote most of its free cash flow this year to repurchasing shares.
DoorDash recorded a 28% revenue increase in 2025, compared with 18% at Uber, whose business also includes ride-hailing.
Amazon, which owns Whole Foods, has also expanded its grocery delivery operations.
DoorDash, valued at roughly $80 billion, acquired Deliveroo and restaurant software firm SevenRooms in 2025, three years after buying European delivery platform Wolt for about $8 billion.
Uber, with a market value of about $135 billion, has agreed this year to pay roughly $15 billion for Delivery Hero and more than $2 billion for workplace catering service ezCater.
The Information reported that Uber’s recent dealmaking could complicate a potential bid for Instacart.
Instacart’s talks with prospective buyers have yet to produce an agreement, and a sale remains uncertain, according to the report.
SBS prověřuje možné porušení povinností vyplývajících ze svěřenského vztahu ze strany vedení společnosti Caesars Entertainment v souvislosti s plánovaným převzetím Tilmanem Fertittou za 5,7 miliardy USD, tedy za 31 USD na akcii.
LOS ANGELES--(BUSINESS WIRE)--Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Caesars Entertainment, Inc. (“Caesars” or “the Company”) (NASDAQ: CZR) for potential breaches of fiduciary duty on the part of its directors and management.
INVESTIGATION DETAILS: The investigation focuses on determining if the Caesars board breached its fiduciary duties to shareholders. Tilman Fertitta has agreed to take Caesars private in a $5.7 billion all-cash deal paying $31 per share.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected]
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Doximity čelí hromadné žalobě kvůli údajnému zamlčení ztráty podílu na trhu; akcie 13. května 2026 klesly o 23 % poté, co společnost nesplnila již snížený výhled tržeb a předpověděla výrazně pomalejší tempo růstu.
San Diego, California--(Newsfile Corp. - October 23, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Doximity, Inc. (NYSE: DOCS) common stock between August 8, 2024 and May 13, 2026, inclusive (the "Class Period"). Doximity is a digital platform for medical professionals that combines health care news, workflow products, and clinician networking.
The complaint alleges that Doximity failed to disclose to investors that it was losing market share to its competitors with more favorable pricing and engagement models.
Investors who suffered significant losses during the Class Period may be eligible to participate in the lawsuit and should contact Robbins LLP for information before the November 16, 2026, lead plaintiff deadline.
Listen to our podcast.
Why Was Doximity Sued?
The complaint alleges that during the Class Period defendants claimed the Company's Newsfeed was its "biggest revenue driver." Specifically, defendants claimed that the Company's growth was "led by our Newsfeed, which is both our most used and most monetized product" and told investors that the Newsfeed was consistently "reach[ing] new highs," with "an all-time record of quarterly active prescribers and double-digit growth in the number of articles read or tapped." In addition, Doximity touted its "deep engagement," assuring investors that Doximity does not "bombard physicians with ads and messages in hopes of getting lucky" and assured investors that "[Doximity does not] have an e-newsletter product." In truth, Doximity overstated the impact that its Newsfeed had on its revenue growth, and the Company was losing market share to its competitors with more favorable pricing and engagement models. Additionally, notwithstanding its frequent statements to the contrary, Doximity relied heavily on both banner ads and email newsletters as advertising methods.
Why Did Doximity Stock Drop?
Plaintiff alleges that on November 6, 2025, despite reporting strong second quarter results, Doximity expressed a degree of caution regarding the outlook for ad spending and implied a slowdown in sales growth in the second half of the 2026 fiscal year, which ended on March 31, 2026. As a result of these disclosures, the price of Doximity common stock declined by $8.29 per share, or 13%.
Then, on February 5, 2026, Doximity lowered its revenue guidance for 2026 full fiscal year, which ended on March 31, 2026, and announced that its sales growth had decelerated while its net income had contracted, which will negatively impact its 2026 fiscal fourth quarter. Following these poor financial results, analysts noted that "uncertainty is lingering. This is not widespread, meaning not all pharma[ceutical] clients are holding back" on their advertising spend. Analysts also began to posit that the reason for Doximity's slowing growth was that the Company was actually losing market share to its competitors. Specifically, an analyst at Evercore noted that older companies, such as Doximity, "are losing share while programmatic, social, and other new formats are gaining share." As a result of these disclosures, the price of Doximity common stock declined by $5.59 per share, or 17%.
Then, on May 13, 2026, Doximity announced that it missed its already-reduced revenue guidance and projected a significantly slower pace of growth for its 2027 fiscal year, which ends on March 31, 2027. As a result, several analysts downgraded Doximity stock citing issues specific to the Company's business. For example, Freeman Capital Markets described the news as "a tough pill to swallow" as shares fell to "an all-time low" and Jefferies placed the stock in the "penalty box." Leerink Partners also put Doximity "in the penalty box" following the "eye-catching" guidance paired with the "shock value" of "[a]ll of the dynamics that lead to the guidance, including market softness, timing of commitments and the spend to ramp its AI products." RBC Capital Markets noted that Doximity's stalled net revenue retention suggested an "increasingly competitive market." As a result of these disclosures, the price of Doximity common stock declined by $5.38 per share, or 23%.
Who May Be Eligible to Participate in the Doximity Class Action?
The lawsuit seeks to represent investors who purchased or otherwise acquired Doximity, Inc. common stock between August 8, 2024 and May 13, 2026. Investors who suffered losses during that period may have legal rights under the federal securities laws.
What Is a Lead Plaintiff?
The lead plaintiff is a court-appointed investor who represents the interests of all class members throughout the litigation. Stockholders who wish to lead the class action should contact Robbins LLP before the November 16, 2026, lead plaintiff deadline.
Serving as lead plaintiff is not required to share in any potential recovery. Investors who do not seek appointment may remain absent class members if the case proceeds and later resolves successfully.
Does It Cost Anything to Participate?
No. Robbins LLP represents investors on a contingency fee basis.
Why Robbins LLP?
A recognized leader in shareholder rights litigation, Robbins LLP represents investors in securities fraud and shareholder derivative litigation. We have helped restore more than $2 billion in value to shareholders and secured some of the largest recoveries in shareholder derivative litigation history.
"Companies have an obligation to provide investors with complete and accurate information so that markets can function fairly and efficiently," said Brian J. Robbins, Founding Partner of Robbins LLP.
To be notified if a class action against Doximity, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Contact Robbins LLP
Investors seeking additional information about the Doximity, Inc. securities class action may contact Robbins LLP by submitting an inquiry, emailing attorney Aaron Dumas, Jr., or calling (800) 350-6003.
Attorney Advertising. Past results do not guarantee a similar outcome.
Facebook
LinkedIn
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320691
Source: Robbins LLP
Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
CoreWeave Stock Faces Fresh Pressure as Higher Rates Threaten AI Boom Summary
UBS lowered its CoreWeave price target to $105 from $120 but maintained its Buy rating, pointing to financing risks and weakening sentiment across AI stocks
CoreWeave CRWV shares dropped 2% in Friday morning trading as UBS cut its price target on the AI computing company to $105 from $120, while keeping its Buy recommendation.
The revised target reflects concerns about financing conditions and investor sentiment rather than a newly identified weakness in the company's operations. UBS analyst Karl Keirstead said demand trends, GPU pricing and CoreWeave's expansion into additional services remain supportive of its business outlook.
CoreWeave faces particular pressure when markets become less receptive to companies that need large amounts of capital. Building AI data centers requires substantial spending, while the company's negative free cash flow and reliance on debt make its valuation more sensitive to higher interest rates.
The stock's decline also comes amid broader uncertainty over how much companies will continue spending on artificial intelligence infrastructure. UBS views that wider reassessment as a key factor weighing on heavily funded AI businesses, rather than evidence that CoreWeave's own business prospects have suddenly weakened.
Although the bank retained its positive rating, the lower price target signals a more cautious view of the stock's near-term potential. Keirstead indicated that a recovery in investor confidence could take time as markets reassess AI investment and financing risks.
Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
ISELIN, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Middlesex Water Company (NASDAQ: MSEX) announced today that its Board of Directors has declared a quarterly cash dividend of $0.38 per share on its common stock, a 5.56% increase from the $0.36 per share dividend last declared in July 2026.
This increase raises the annual dividend rate to $1.52 from $1.44 per share of common stock and marks Middlesex Water Company’s (“Middlesex”) 54th consecutive year of dividend increases. The dividend at the new rate is payable December 1, 2026, to shareholders of record as of November 16, 2026. Middlesex has paid cash dividends in varying amounts each year since 1912.
About Middlesex Water Company
Middlesex Water Company (“Middlesex”) is one of the nation’s premier investor-owned water and wastewater utilities. Established in 1897, Middlesex is a trusted provider of life-sustaining services to more than half a million people in New Jersey and Delaware. The company focuses on employee engagement, operational excellence, superior customer experience, investment in infrastructure, and selective and sustainable growth to deliver value to our customers, investors, and the communities we serve.
Media Relations:
Rebecca Stenholm
Vice President, Communications and Corporate Affairs
[email protected]
(908) 565-2491
Investor Relations:
Jennifer Ketschke
Director, Investor Relations and Treasury
[email protected]
(732) 638-7523
From a valuation perspective, Syntec Optics Holdings, Inc. (OPTX - Free Report) stock looks expensive. OPTX is currently trading at a trailing 12-month enterprise value/sales (EV/sales) of 8.77X, above the industry average of 2.78X. OPTX also trades at a higher valuation compared to other industry players, such as Duos Technologies Group, Inc. (DUOT - Free Report) and Bit Digital, Inc. (BTBT - Free Report) . Currently, DUOT and BTBT trade at EV/sales multiples of 2.42X and 2.21X, respectively.
Image Source: Zacks Investment Research
While this elevated valuation reflects investor confidence in the company’s long-term potential, it also raises concerns about whether the stock can justify such lofty multiples. Considering the premium valuation, investors must be wondering whether they should buy, hold or sell the stock.
OPTX Stock’s Price PerformanceSyntec Optics shares have jumped 135.3% over the past year against the industry’s 28.7% decline. The Zacks Business Services sector has fallen 14.4% while the S&P 500 has advanced 13.2%. Meanwhile, OPTX has outperformed DUOS and BTBT, which declined 36.8% and 76.8%, in the same time frame.
Image Source: Zacks Investment Research
Business Tailwinds for OPTXSyntec Optics is benefiting from expanding demand for precision optics across U.S. defense platforms. In September 2026, the company reported more than $9 million in purchase orders, more than double its previously announced total. Demand spans missile-guidance optics, night-vision equipment, specialized targeting lasers and AI-enabled augmented-reality headsets. The breadth of applications and recurring orders could support production visibility as defense customers modernize their systems and deploy advanced optical technologies.
OPTX's space business is gaining traction through orders tied to national security and satellite communications. In September 2026, it secured an order for optics supporting U.S. Space Force infrastructure and reconnaissance satellites. The company is also ramping weekly shipments of precision waveguides for satellite antenna feeds. Management indicated that its space antenna portfolio could generate more than $1 million in annual revenues, while potential demand from expanding satellite constellations supports a longer-term opportunity.
Syntec Optics strengthened its lunar exploration exposure in October 2026 by announcing recurring production orders for precision components used in actuators on NASA's Artemis III rockets. These components help maintain engine positioning and flight trajectory. Management said the award increased its space technology backlog by 10%. The evolving mission plan, including orbital testing ahead of lunar operations, could provide additional production opportunities, although the timing and scale of future orders remain dependent on mission execution.
Syntec Optics is broadening its presence in AI infrastructure and advanced energy applications. In August 2026, it reported more than $4 million in orders linked to data center technologies and new fusion-energy orders valued at seven times those secured late in 2025. Its precision optics are designed for demanding fusion reactor environments, while micro-connectors and space-power systems expand the addressable product portfolio. Dedicating 5% of factory capacity to AI data center optics signals plans to build repeatable production in this market.
Improving financial flexibility could help Syntec Optics pursue its growing order pipeline. The company raised approximately $18.6 million in net proceeds through an April 2026 share offering and another $2.8 million from the underwriter's option exercise. It used roughly $6.8 million to repay debt and eliminated its bank credit line and related financial covenants. Sales increased to $14.8 million in the first half of 2026 from $13.6 million a year earlier, while operating cash flow improved to $0.2 million from $0.1 million.
Headwinds for OPTX’s BusinessSyntec Optics faces profitability pressures despite revenue growth. In the first half of 2026, gross profit declined to $3.1 million from $3.9 million a year earlier, as higher material costs, particularly aluminum, weighed on margins. The company reported a net loss of $0.6 million compared with nearly breakeven results a year ago. Customer concentration remains a concern, with three customers accounting for 52% of revenues. Competition from larger manufacturers, fluctuations in product mix and potential production disruptions could further pressure margins.
ConclusionOPTX’s growing defense and space orders, expanding AI infrastructure opportunities and improved financial flexibility support its long-term growth prospects. However, margin pressures, rising material costs, customer concentration and profitability challenges warrant caution.
Also, its valuation is higher than the industry average. For long-term investors, OPTX’s strong fundamentals may justify holding the stock, but investors looking to add the stock to their portfolios may want to wait for a better entry point.
SummaryCerebras Systems Inc. has fallen 69% from its $386 peak, while Q2 core revenue still grew 103% year over year.RPO reached $25.4 billion, cash exceeded $8.6 billion, and management expects 2027 core revenue to more than triple.AMD integration could increase throughput around 5x, but customer deployment and real revenue conversion remain the key proof points.At $109, CBRS stock valuation still looks expensive today, but 2027 consensus sales imply a much lower 9.5x P/S multiple. NiseriN/iStock via Getty Images
With Cerebras Systems Inc. (CBRS) now around $109, I don't think it makes much sense anymore to discuss how expensive the stock was near $386. What matters to me now is whether this big decline has created an
8.78K Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in CBRS over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
První skládací iPhone Duo od společnosti Apple s cenou 1 999 USD si vysloužil chválu recenzentů, uživatelé na Redditu však již hlásí praskání displeje v oblasti pantu.
Apple’s first foldable iPhone is drawing praise for its sleek engineering and nearly invisible screen crease — but critics say its hefty design, camera compromises and uneven app support make the $1,999 gadget a tough sell for most consumers.
On top of that, early reports indicate the pricey device may be prone to crack.
The iPhone Duo hits stores Friday after drawing an 8.8 out of 10 from Engadget and 7 out of 10 from both The Verge and WIRED.
An image posted by a Reddit user shows a damaged iPhone Duo. reddit/Bitter_Offer7123
Engadget called Apple’s long-awaited entry into the foldable market “worth the wait,” while The Verge described it as a “messy, expensive, good time.”
Meanwhile, Wired called it an “astonishingly good first foldable.”
The device unfolds to reveal a 7.6-inch matte display that dramatically reduces glare, while its innovative hinge operates smoothly and holds the screen at different angles.
However, a handful of Reddit posts indicated severe disappointment for some buyers as of Friday afternoon.
“iPhone Duo screen cracked within 6 hours of ownership,” one user complained.
The person said they had taken out the device to show it off to a friend when they “felt something around the internal hinge, underneath the screen.”
“As I continued opening it, I heard an audible crack, and the screen broke right along the hinge,” the post continued. “There were no marks or damage on the inner screen’s surface or the external hinge to suggest anything had been caught or damaged.”
The person zoomed back to an Apple store, where staff gave the customer a new Duo.
Another Reddit user posted a video of a cracked device, commenting: “Looks like some of them are cracking in the exact same area.”
Yet another image of a cracked Duo had the caption, “I’ve seen several iPhone Duos with damage in this exact same spot.”
A display of iPhone Duo smartphones is seen during a launch in Manhattan on Friday. Anadolu via Getty Images
Still, reviewers sung praises of the device’s titanium construction and smooth folding mechanism.
The crease hasn’t disappeared entirely, however. Several critics noted that it remains visible at certain angles and can still be felt when running a finger across the screen.
Apple’s anti-reflective finish also comes with a trade-off: Colors can appear less vibrant and blacks less deep than on the company’s non-folding premium iPhones.
At 254 grams and 11.3 millimeters thick when folded, the Duo’s bulk emerged as one of the most frequent complaints.
Its relatively small 5.4-inch outer display also drew mixed reactions, with some reviewers praising its compact footprint and others complaining that websites and apps feel cramped on the device.
The Wall Street Journal delivered one of the harshest assessments, describing the device as “Too Much iPhone, Too Little iPad.”
A display of iPhone Duo smartphones is seen during the launch in Manhattan on Friday. Anadolu via Getty Images
Despite its expansive inner display, the Duo falls short of an iPad when it comes to productivity, with more limited multitasking and keyboard capabilities, according to the Journal.
Software emerged as another major sticking point.
While Apple’s own apps generally make a seamless transition between the folded and unfolded screens, reviewers found that many third-party offerings weren’t properly optimized for the device.
Wired’s Julian Chokkattu described the problem: “Thick, black bars on the sides, with a phone-sized app in the middle of this tablet-like display.”
Engadget’s Sam Rutherford called the gap between optimized and unoptimized apps “the biggest growing pain you’ll face on Apple’s first foldable.”
Even the Duo’s multitasking capabilities have limitations.
Users can run two apps side by side, but Apple’s software restricts them to a fixed 50-50 split, without the freedom to open a third floating window.
Suraya Shivji, 28, a New York resident visiting San Francisco for a friend’s wedding, reacts to seeing the iPhone Duo in action at the Apple Union Square store in San Francisco on Friday. REUTERS
“If you have two apps split-screen on the Duo, Apple won’t let you resize one app to be slightly bigger than the other like you can on Android,” Chokkattu wrote in Wired.
“Here, a 50-50 split is always enforced. You can’t add a floating third app when in split-screen either, even though Apple has offered a similar capability on iPads for years.”
Those complaints could ease as developers adapt their apps to the new format.
Wired reported that several popular apps received updates during the device’s testing period, while Creative Strategies said the share of its installed apps optimized for the Duo increased dramatically over roughly six days.
Other shortcomings won’t be fixed with software updates.
“Despite being Apple’s most expensive iPhone, the iPhone Duo does not have its most powerful camera system,” Chance Miller of 9to5Mac wrote.
Its main and ultrawide cameras generally earned favorable marks, but several reviewers found their performance inferior to the iPhone 18 Pro, particularly in low light.
The hidden 4-megapixel camera beneath the inner display also disappointed, with Gizmodo reporting washed-out image quality.
An image provided by a Reddit user shows iPhone Duo models with damage in the exact same spot. reddit/robnaught
“I hear you: it feels absurd that a $2,000 phone—the most expensive iPhone ever—does not have the most versatile camera system that Apple has to offer,” Gizmodo’s Raymond Wong wrote, adding that he “noticed more lens flares coming off streetlights and more smeared details.”
Still, the folding design offers some novel photographic advantages, including the ability to use the higher-quality rear cameras for selfies while viewing the shot on the outer screen.
Battery life, meanwhile, exceeded the expectations of several reviewers, even if it couldn’t match Apple’s top conventional iPhone.
Tom’s Guide found that the Duo lasted 13 hours and 20 minutes in a continuous 5G web-browsing test using its larger display.
That handily beat the 10 hours and six minutes recorded by Samsung’s Galaxy Z Fold 8, but fell well short of the iPhone 18 Pro Max’s 17 hours and 31 minutes.
Other reviewers reported getting through a typical day without needing to recharge, although intensive use of the larger screen could drain the battery considerably faster.
The divergent ratings reflected less disagreement over the Duo’s strengths and weaknesses than differing views about whether its folding design justifies the compromises.
Tom’s Guide called it the “best designed foldable yet,” while 9to5Mac concluded that a conventional iPhone remains the more practical choice for most consumers.
Amazon AMZN stands out among consumer stocks as Bank of America (BofA) data show heavy withdrawals from consumer-focused funds, highlighting a divide between investor sentiment toward the broader sector and the quantitative appeal of individual companies.
Amazon received a quantitative score of 4.95 out of five in the supplied ranking, putting it at the top of the consumer-stock list. The scoring approach considers factors such as valuation, growth, profitability, earnings estimate revisions and share-price momentum relative to sector peers.
The broader fund-flow trend remains a concern. BofA's figures show consumer fund withdrawals accelerating, with the four-week moving average falling further into negative territory. That suggests investor caution may extend beyond short-term market fluctuations.
Amazon's diversified business spans online retail, cloud computing through Amazon Web Services, advertising and digital services. Those operations give the company several sources of growth, although a favorable quantitative score alone does not guarantee future share-price gains.
For investors, the key question is whether Amazon's business performance can continue to support its valuation while sentiment toward consumer-related investments weakens.
Amazon před zveřejněním výsledků čelí otázkám ohledně návratnosti investic do AI: tržby AWS ve 2. čtvrtletí vzrostly o 37 % a provozní zisk dosáhl 16,6 miliardy USD.
Amazon heads into Thursday's report after AWS operating income reached $16.6 billion, with AI investment returns in focus. -
Summary
AWS margins, capital spending and capacity constraints are key measures to watch.
Amazon, the commerce and cloud-computing giant AMZN, traded at $248.96, down 0.57%, at 10:00 a.m. ET ahead of Thursday's earnings report. The modest decline leaves the bigger question untouched: how much profit can Amazon squeeze from its AI infrastructure spending? Reuters' earnings preview frames the coming reports as a test of whether that investment can deliver durable returns.
The hurdle is already high. Amazon reported second-quarter AWS revenue growth of 37%, its fastest pace in 18 quarters, alongside $16.6 billion in cloud operating income. Companywide operating income climbed 43% to $27.5 billion. Management's third-quarter operating-income forecast of $22.5 billion to $26.5 billion puts the next report's profitability firmly in focus.
The GuruFocus snapshot shows a GF Score of 93/100, with growth its strongest category and financial strength comparatively weaker. That supports a strong operating profile, but it does not settle the spending question. Watch AWS margins, capital expenditures and capacity constraints together. Faster cloud growth carries more weight when the returns hold up after power, depreciation and chip costs.
Disclosures
I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
Tržby AWS ve 2. čtvrtletí 2026 meziročně vzrostly o 36,7 % na 42,2 miliardy USD, což představuje nejrychlejší růst za 18 čtvrtletí, a to díky poptávce po AI.
Amazon survived a brutal 50% stock collapse, a CEO transition, and its first losing year in nearly a decade, then came roaring back with cloud growth nobody saw coming. Whether you bought in last year or ten years ago changes…
How an Online Store Became a Cloud and Ad Empire
A decade ago, Amazon (NASDAQ:AMZN | AMZN Price Prediction) was mostly an online store with a promising cloud side business. Over the decade that followed, AWS became the dominant profit engine, Prime grew alongside a huge logistics expansion, and advertising turned into a giant that brought in $19.8 billion in Q2 2026 alone, up 26%.
The pandemic sent e-commerce demand surging, and Andy Jassy succeeded Jeff Bezos as CEO in July 2021. Then the bill came due. Amazon overbuilt its fulfillment network, posted its first unprofitable year since 2014 in 2022, and the stock fell roughly 50%.
AI Pushed AWS Back Into High Gear
Cost discipline under Jassy brought margins back, and AI demand revived cloud growth. AWS revenue rose 36.7% to $42.2 billion in Q2 2026, its fastest growth in 18 quarters. The company’s AI and chips businesses each passed run rates of more than $25 billion.
Your $1,000 Grew to $5,966 Over the Decade
1-Year Return
Initial Investment: $1,000
Current Value: $1,148.80
Total Return: 14.88%
S&P 500 (same period): $1,140.90 (14.09%)
5-Year Return
Initial Investment: $1,000
Current Value: $1,499
Total Return: 49.9%
Annualized Return: 8.4%
S&P 500 (same period): $1,681.50 (68.15%)
10-Year Return
Initial Investment: $1,000
Current Value: $5,966
Total Return: 496.6%
Annualized Return: 19.6%
S&P 500 (same period): $3,545.60 (254.56%)
Timing explains almost everything here. The 10-year buyer got in before AWS and Prime fully took off and still finished well ahead of the index, even after sitting through the 2022 collapse. The 5-year buyer came in near the pandemic high, absorbed that same drop, and has trailed the S&P 500. Over the past year, Amazon roughly matched the market, and shares fell 4.57% on October 22 alone.
I Lean Bullish, With a Close Eye on Spending
I’d put $1,000 into Amazon today if AWS keeps turning its $496 billion backlog into high-margin revenue. Jassy says AWS could “very possibly be a trillion-dollar annual revenue business for us in time,” and advertising, grocery, and custom chips add growth that has nothing to do with cloud.
But I’d avoid it if spending exceeds the return. Amazon expects about $220 billion in 2026 cash capex, trailing free cash flow has turned negative at -$7.6 billion, and Anthropic gains boost GAAP earnings, including $53.4 billion pre-tax in Q2. At a P/E near 35, investors are paying up front for that expansion.
I lean bullish. The slow five-year stretch reflects a costly restructuring and a heavy investment cycle, and the AWS numbers suggest that cycle is starting to pay off. The next earnings report is the key test: I want AWS growth to hold up and capex to start bringing in revenue.
Contact [email protected] for any questions or corrections.
Akcionáři Canopy Growth schválili zmocnění představenstva ke konsolidaci akcií v poměru 1:5 až 1:15, o níž může představenstvo rozhodnout do 23. října 2027.
The 2026 Cannabis Wildcard: How Tax Reform Could Reset Stock ValuationsCanopy Growth NASDAQ: CGC shareholders approved all matters presented at the company’s reconvened 2026 Annual General and Special Meeting, including a share-consolidation authorization, the election of five directors and the appointment of MNP LLP as auditor for fiscal 2027.
The virtual meeting, which had been adjourned on Sept. 25, 2026, was reconvened on Oct. 23. Chief Executive Officer and Director Luc Mongeau chaired the session and said proxies representing enough common shares had been received to establish quorum.
Get Canopy Growth alerts:
Board Election and Auditor Appointment Constellation Brands: A Fallen Star or a Hidden Value Play?Shareholders elected all five board nominees: Mongeau, David Lazzarato, Theresa Yanofsky, Shan Atkins and Joseph Bayern. The directors will serve until the next annual general meeting or until their successors are elected or appointed.
Investors also approved the appointment of MNP LLP as Canopy Growth’s independent registered public accounting firm for fiscal 2027. The board, or an appropriate committee, was authorized to set the firm’s remuneration.
Profit from the Green Wave: Top Cannabis Stocks to WatchThe company presented its audited consolidated financial statements for the fiscal year ended March 31, 2026. No shareholder vote was required for the presentation of those financial statements.
Share Consolidation Authorized Among the approved proposals was a special resolution authorizing an amendment to Canopy Growth’s articles to consolidate its issued and outstanding common shares and exchangeable shares.
The board may determine the precise consolidation ratio, within a range of one post-consolidation share for every five to 15 pre-consolidation shares, at any time before Oct. 23, 2027. The same ratio would apply to common and exchangeable shares. Fractional shares resulting from the consolidation would be deemed tendered to the company for cancellation without consideration, as described in the company’s proxy statement.
Governance and Compensation Proposals Shareholders also approved an advance-notice bylaw establishing notice and other requirements for shareholders seeking to nominate directors at company shareholder meetings.
In addition, shareholders approved the renewal of unallocated awards under Canopy Growth’s omnibus incentive plan, including options, restricted share units, deferred share units, share-based awards and other entitlements.
The company’s advisory, non-binding say-on-pay proposal concerning named executive officer compensation also passed. Shareholders voted in favor of holding future advisory votes on executive compensation annually under the say-on-frequency proposal.
All director nominees were elected. MNP LLP was appointed as auditor for fiscal 2027. The board received authority to implement a share consolidation within the approved range. Shareholders approved the advance-notice bylaw and omnibus incentive-plan renewal. Investors supported executive compensation and selected an annual say-on-pay vote. Christelle Gedeon, Canopy Growth’s Chief Business Development and Corporate Affairs Officer and Corporate Secretary, said all items submitted to a ballot received the required shareholder approval. The company said final voting results, including votes cast for and withheld on each matter, would be reported through SEDAR+, a press release and a Form 8-K filing.
No questions were submitted by shareholders during either the formal-business portion of the meeting or the subsequent question-and-answer session.
About Canopy Growth (NASDAQ:CGC)Canopy Growth Corporation is a cannabis company headquartered in Smiths Falls, Ontario, Canada. Founded in 2013, the company operates in the production, distribution and sale of cannabis and cannabis-related products for adult-use and medical markets.
Its product portfolio includes dried cannabis flower, pre-rolls, cannabis oils, softgels, vapes, beverages and edibles. Canopy Growth markets products under several brands, including Tweed, 7ACRES, Doja and Deep Space, with offerings designed for different consumer preferences and product segments.
Canopy Growth primarily serves the Canadian recreational and medical cannabis markets and has pursued international opportunities in selected medical-cannabis markets.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Canopy Growth Right Now?Before you consider Canopy Growth, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Canopy Growth wasn't on the list.
While Canopy Growth currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
SAP ve 3. čtvrtletí zvýšil objem budoucích cloudových kontraktů o 26 % na 24,1 mld. EUR při konstantních měnových kurzech; tržby z cloudu vzrostly o 25 %.
Enterprise software and business AI provider SAP SAP traded at $238.40, down 0.91%, at 10:24 a.m. ET on Friday. According to AD HOC News, BMO raised its price target to $265 from $235 and maintained Outperform. That puts the target roughly 11.2% above the share price. The analyst sees room to climb. Investors still need execution.
The business has momentum. SAP's third-quarter release reported €24.1 billion in current cloud backlog, up 26% at constant currencies, alongside 25% cloud revenue growth. Cloud ERP Suite revenue increased 28% on the same basis, while operating profit rose 18% under both IFRS and adjusted measures. Quarterly revenue topped €10 billion for the first time, and adjusted operating profit crossed €3 billion. Those milestones put real earnings behind the cloud story.
The valuation leaves something to prove. A GF Score of 90/100 signals broad fundamental strength, while a 29.15 price-to-earnings ratio makes sustained earnings growth central to the investment case. BMO's target increase amounts to 12.8%, but a higher target does not convert contracts into sales. The next test is whether SAP can turn its growing backlog into revenue while keeping profit growth strong.
FDA schválila společnosti AbbVie podkožní zahajovací režim přípravku SKYRIZI pro dospělé se středně až těžce aktivní Crohnovou nemocí, který umožňuje zahájit léčbu doma.
Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the course of treatment In the pivotal Phase 3 AFFIRM study, subcutaneous (SC) SKYRIZI® achieved superior clinical remissioni and endoscopic responseii at week 12 compared with placebo in patients with Crohn's disease; results were particularly strong in patients without prior advanced therapy failureiii The safety profile of subcutaneous induction was generally consistent with the established SKYRIZI profile in Crohn's disease, with no new safety risks identified FDA also approved an update to the U.S. Prescribing Information warning and precautions across all indications to allow healthcare providers to use clinical judgment when determining whether tuberculosis (TB) testing is needed , /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active Crohn's disease (CD)iv. Patients now have the option to start SKYRIZI treatment at home, with induction doses delivered by an on-body injector (OBI) induction pack and then continue using an OBI once every eight weeks throughout the course of maintenance treatment.
"People living with Crohn's disease need treatments that can deliver meaningful disease control from the start," said Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, AbbVie. "With the approval of subcutaneous induction, we are building on the strong efficacy of SKYRIZI while giving patients and physicians greater flexibility in how treatment is initiated. This is one more example of how AbbVie continues to advance treatment to better meet the needs of people living with Crohn's disease."
Subcutaneous SKYRIZI Shows High Rates of Clinical Remission and Endoscopic Response by Week 12iii
This FDA approval is supported by positive results from the Phase 3 AFFIRM trial evaluating the efficacy and safety of SC SKYRIZI versus placebo in patients with moderately to severely active CD.iii SKYRIZI achieved superiority of the co-primary endpoints of clinical remission and endoscopic response at week 12.iii Although the study enrolled a primarily treatment-refractory population, these Phase 3 results were particularly strong within patients without prior advanced therapy failure (advanced therapy-naïve).iii By week 12, nearly three-quarters (74%) of advanced therapy (AT)-naïve patients were in clinical remission (vs. 27% placebo) and these AT-naïve patients achieved endoscopic response at four times the rate of placebo (60% vs. 15%, respectively).iii SC SKYRIZI also had a higher efficacy response in patients who had previously failed advanced therapy.iii
SC SKYRIZI also met secondary endpoints including endoscopic remission and FACIT fatigue scores at week 12 vs. placebo.iii The safety profile of SC SKYRIZI for induction was generally consistent with its known profile in CD, with no new safety risks observed.iii
Together, these results demonstrate market-leading clinical and endoscopic outcomes in advanced therapy-naïve patients that set a high bar in CD. Furthermore, the strength of these subcutaneous results provides a compelling foundation for future clinical trials.
AFFIRM Phase 3 Proportion of Patients Meeting Efficacy Endpoints at Week 12iii
Total Population
Prior Advanced Therapy
Failurea
Without Prior Advanced
Therapy Failureb
(Advanced Therapy-Naïve)
Proportion of
Patients
Placebo
N=94
Skyrizi SCc
N=180
Placebo
N=61
Skyrizi SCc
N=115
Placebo
N=33
Skyrizi SCc
N=65
Clinical
Remissiond,e
30 %
56 %h
31 %
45 %
27 %
74 %
Endoscopic
Responsed,f
15 %
43 %h
15 %
33 %
15 %
60 %
Endoscopic
Remissiong
11 %
26 %h
11 %
17 %
9 %
43 %
a. Prior advanced therapy failure includes inadequate response, loss of response, or intolerance to one or more biologic or Janus Kinase inhibitor (JAKi) treatments for CD
b. Without prior advanced therapy failure includes patients who were naïve to biologics or JAKi, or patients who had never failed or demonstrated intolerance to biologics or JAKi
c. SKYRIZI 720 mg as a subcutaneous injection at Week 0, Week 2, Week 4, and Week 8
d. Co-primary endpoints
e. Defined as Crohn's disease activity index (CDAI) < 150
f. Defined as a decrease in Simplified Endoscopic Activity Score for Crohn's disease (SES-CD) > 50% from baseline, or a decrease of at least 2 points for subjects with a baseline
score of 4 and isolated ileal disease, based on central reading
g. SES-CD ≤ 4 and at least a 2-point reduction from baseline, with no individual subscore greater than 1, based on central reading
h. p <0.001 compared to placebo in total population.
Subcutaneous Treatment With SKYRIZI Offers Fully Self-Administered Therapy From the Start
The induction dosing regimen with SC SKYRIZI is 720 mg delivered by OBI induction pack at weeks 0, 2, 4 and 8.iii Patients also have the option to start treatment intravenously with 600 mg delivered at weeks 0, 4 and 8.iii Patients can then continue with maintenance dosing starting at week 12 administered by OBI every eight weeks.iii
"When patients and I discuss treatment, they want to know two things: will it work? And how will it fit into their lives?" said Millie D. Long, M.D., MPH, chief, division of gastroenterology and hepatology, University of North Carolina at Chapel Hill, and lead investigator of AFFIRM. "AFFIRM answered the first question, with superior rates of clinical remission and endoscopic response versus placebo during induction with subcutaneous SKYRIZI, particularly in patients new to advanced therapy. This approval answers the second. As a physician who has used the SKYRIZI OBI, I've seen firsthand the convenience it can offer patients. Now with this approval, patients can start treatment at home and continue the same way through maintenance."
Patients Report Satisfaction and Ease of Use in Real World Experience With SKYRIZI OBI
First introduced in 2022 for CD maintenance treatment, the SKYRIZI OBI has demonstrated strong user experience. In a real-world survey of 186 people living with CD, 88% reported AbbVie's OBI easy to use.v In evaluating alternative routes of administration, a patient-reported survey of 352 adults living with IBD found 87% were satisfied or highly satisfied with OBI compared to 71% with an autoinjectorvi, demonstrating patient preference for OBI.
FDA Also Approved Update to Tuberculosis (TB) Language in U.S. Prescribing Information
Additionally, the FDA approved an update to the SKYRIZI prescribing information's warning and precautions language across all approved indications.iii The revised label advises healthcare providers to consider TB evaluation prior to treatment initiation based on clinical judgment.iii This change gives healthcare providers greater flexibility in patient assessment before starting SKYRIZI treatment. There is no mandatory TB test prior to initiating SKYRIZI.
About Crohn's Disease
Crohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal tract, most commonly in the area between the small intestine (ileum) and the colon, causing persistent diarrhea and abdominal pain.vii,viii It is a progressive disease, meaning it gets worse over time and may lead to life-threatening complications or surgery.ix,x Because the signs and symptoms of Crohn's disease are unpredictable, it causes a significant burden on people living with the disease—not only physically but also emotionally and economically.xi
About the AFFIRM Studyxii
AFFIRM is a global, Phase 3, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of risankizumab subcutaneous (SC) as an induction treatment in adult patients with moderately to severely active Crohn's disease. Co-primary endpoints were percentage of participants with CDAI Clinical Remission (CDAI < 150) and percentage of participants with endoscopic response at week 12. A total of 274 patients were randomized in a 2:1 ratio to risankizumab SC or placebo. Key demographics and baseline characteristics were generally balanced between the risankizumab SC and placebo groups; 65% had failed advanced therapies for the treatment of CD before. The study consists of three treatment periods: a placebo-controlled Period A (baseline to week 12) to evaluate the efficacy and safety of risankizumab SC induction treatment, an extended Period B (week 12 to 24) where patients receive blinded or open-label treatments based on their clinical response at week 12, and a 52-week open-label extension Period C where all patients receive the approved risankizumab maintenance treatment.xii More information on this trial can be found at www.clinicaltrials.gov (NCT06063967).xii
Patient Access and Support
AbbVie is committed to helping people access SKYRIZI and other medicines, including offering a patient support program and co-pay card that may reduce out-of-pocket costs to as little as $0 per month for eligible, commercially insured patients. For those with limited or no health insurance, AbbVie offers myAbbVie Assist, a patient assistance program that provides SKYRIZI at no charge to those who qualify. More information about this assistance program can be found at www.AbbVie.com/myAbbVieAssist.
About SKYRIZI® (risankizumab-rzaa)
SKYRIZI is an interleukin-23 (IL-23) inhibitor that blocks IL-23 by selectively binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases.iii SKYRIZI is approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderately to severely active ulcerative colitis, plaque psoriasis, psoriatic arthritis and Crohn's disease.iii
SKYRIZI® (risankizumab-rzaa) U.S. Uses and Important Safety Informationiii
SKYRIZI is a prescription medicine used to treat:
moderate to severe plaque psoriasis in adults and children 6 years of age and older who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy). active psoriatic arthritis in adults and children 6 years of age and older. moderately to severely active Crohn's disease in adults. moderately to severely active ulcerative colitis in adults. IMPORTANT SAFETY INFORMATION
What is the most important information I should know about SKYRIZI® (risankizumab-rzaa)?
SKYRIZI is a prescription medicine that may cause serious side effects, including:
Serious allergic reactions:
Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction: fainting, dizziness, feeling lightheaded (low blood pressure) swelling of your face, eyelids, lips, mouth, tongue, or throat trouble breathing or throat tightness chest tightness skin rash, hives itching Infections:
SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider may check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.
Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including: fever, sweats, or chills cough shortness of breath blood in your mucus (phlegm) muscle aches warm, red, or painful skin or sores on your body different from your psoriasis weight loss diarrhea or stomach pain burning when you urinate or urinating more often than normal Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.
Before using SKYRIZI, tell your healthcare provider about all of your medical conditions, including if you:
have any of the conditions or symptoms listed in the section "What is the most important information I should know about SKYRIZI?" have an infection that does not go away or that keeps coming back. have TB or have been in close contact with someone with TB. have recently received or are scheduled to receive an immunization (vaccine). Medications that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine. are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk. become pregnant while taking SKYRIZI. You are encouraged to enroll in the Pregnancy Registry, which is used to collect information about the health of you and your baby. Talk to your healthcare provider or call 1-877-302-2161 or visit http://glowpregnancyregistry.com to enroll in this registry. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of SKYRIZI?
SKYRIZI may cause serious side effects. See "What is the most important information I should know about SKYRIZI?"
Liver problems may happen while being treated for Crohn's disease or ulcerative colitis: A person with Crohn's disease who received SKYRIZI through a vein in the arm developed changes in liver blood tests with a rash that led to hospitalization. Your healthcare provider will do blood tests to check your liver before, during, and at least up to 12 weeks of treatment, and may stop treatment with SKYRIZI if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: unexplained rash, nausea, vomiting, stomach (abdominal) pain, tiredness (fatigue), loss of appetite, yellowing of the skin and eyes (jaundice), and dark urine.
The most common side effects of SKYRIZI in people treated for Crohn's disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, injection site reactions, low red blood cells (anemia), fever, back pain, urinary tract infection, and rash.
The most common side effects of SKYRIZI in people treated for plaque psoriasis and psoriatic arthritis include: upper respiratory infections, headache, feeling tired, injection site reactions, and fungal skin infections.
These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.
Use SKYRIZI exactly as your healthcare provider tells you to use it.
SKYRIZI (risankizumab-rzaa) is available in a 150 mg/mL prefilled syringe and pen, a 55 mg/0.37 mL prefilled syringe, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie may be able to help.
Visit AbbVie.com/PatientAccessSupport to learn more.
Please click here for the Full Prescribing Information and Medication Guide.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For nearly 30 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology, dermatology and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.
Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 20+ immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
References:
i. Co-primary endpoint defined as Crohn's Disease Activity Index (CDAI) score <150.
ii. Co-primary endpoint defined as decrease in SES-CD > 50% from baseline (or for patients with isolated ileal disease and a baseline SES-CD of 4, at least a 2-point reduction from baseline), as scored by a central reviewer.
iii. SKYRIZI [Package Insert]. North Chicago, IL: AbbVie Inc.
iv. Defined as CDAI of 220 to 450 and SES-CD ≥ 6 (or ≥ 4 for isolated ileal disease).
v. Keefer L, Griffith JM, Yang M, et al. Treatment satisfaction and patients' experiences with risankizumab on-body injector among adults with Crohn's disease in clinical practice: initial results from the ASPIRE-CD study. Poster P5425. Presented at: American College of Gastroenterology Annual Scientific Meeting; October 24-29, 2025; Phoenix, AZ.
vi. Data on file, AbbVie Inc. Source: ZS Associates; December 2024-February 2025.
vii. Crohn's & Colitis Foundation. The facts about inflammatory bowel diseases. Crohn's & Colitis Foundation. Published November 2014. Accessed October 13, 2026. https://www.crohnscolitisfoundation.org/sites/default/files/2019-02/Updated%20IBD%20Factbook.pdf.
viii. Mayo Clinic. Crohn's disease - Symptoms and causes. Mayo Clinic. Accessed February 23, 2026. https://www.mayoclinic.org/diseases-conditions/crohns-disease/symptoms-causes/syc-20353304.
ix. Mehta F. Report: economic implications of inflammatory bowel disease and its management. Am J Manag Care. 2016 Mar;22(3 Suppl):s51-60.
x. Kaplan G. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):720-7. doi: 10.1038/nrgastro.2015.150.
xi. Gajendran M, et al. A comprehensive review and update on Crohn's disease. Dis Mon. 2018 Feb;64(2):20-57. doi: 10.1016/j.disamonth.2017.07.001.
xii. ClinicalTrials.gov. A Study to Evaluate Efficacy and Safety of Risankizumab Subcutaneous Induction in Participants With Moderately to Severely Active Crohn's Disease (AFFIRM). NCT06063967. Available at: https://clinicaltrials.gov/study/NCT06063967. Accessed October 13, 2026.
Palantir uvedl, že ani firma, ani americká vláda nemohou na dálku vypnout systém Maven, který NATO v roce 2025 pořídilo pro evropské vojenské velitelství.
Defense-AI software provider Palantir PLTR told Reuters that neither the company nor the U.S. government can remotely disable customers' Maven systems, as shares traded at $195.25, down 0.48% at 10:35 a.m. ET Friday. The statement addresses a central concern for European military buyers: who controls the technology once it is deployed?
According to Reuters' reporting, NATO purchased Maven for its European military headquarters in 2025 and declared full technical operating capability in June 2026. The platform brings together battlefield information from sources including satellites and radar. Palantir's latest reported quarterly revenue reached $1.94 billion, up 93%, with U.S. revenue rising 115% to $1.57 billion. That puts European adoption alongside an already fast-growing American business.
The valuation leaves little room for complacency. A GF Score of 83/100 sits alongside a price-to-earnings ratio of 166.31, suggesting solid business metrics come with demanding earnings expectations. Customer control addresses one technical concern, but governments still have to weigh sovereignty, security and oversight. For investors, the next meaningful signals are additional deployments, renewals and disclosed contract values. Those would show whether NATO's adoption translates into a broader European business.
SBS prověřuje možné porušení povinností vedení společnosti Roku vůči akcionářům v souvislosti s plánovaným převzetím společnosti Fox Corporation za 22 miliard USD, tedy 160 USD za akcii.
LOS ANGELES--(BUSINESS WIRE)--Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Roku, Inc. (“Roku” or “the Company”) (NASDAQ: ROKU) for potential breaches of fiduciary duty on the part of its directors and management.
INVESTIGATION DETAILS: The investigation focuses on determining if the Roku board breached its fiduciary duties to shareholders. The Company to be acquired by Fox Corporation at an enterprise value of $22 billion, or $160 per share.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected]
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Investors await next Thursday's results as strong prescription volumes face lower realized prices. -
Summary
Full-year revenue guidance stands at $85 billion–$87 billion.
Diabetes and obesity-drug maker Eli Lilly LLY traded at $1,284.51, down approximately 1.70% at 10.09am EST, on October 23. With earnings due next Thursday, according to Reuters' earnings preview, the key question is whether surging demand can keep overpowering weaker pricing.
Lilly's second-quarter results put that tension in numbers: revenue climbed 48% to $23 billion as volume increased 60%, while realized prices declined 13%. Mounjaro and Zepbound generated roughly $14.9 billion combined. Management raised its full-year revenue outlook to $85 billion–$87 billion, setting a demanding benchmark for the next report.
The valuation picture shows shares 19.01% below the GF Value estimate of roughly $1,590, suggesting potential upside against that model rather than a guaranteed bargain. Demand is powerful. Turning it into profitable growth remains the test. Investors should watch realized pricing, gross margin and manufacturing progress to judge whether higher prescription volumes are delivering enough earnings power.
Disclosures
I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
Broadcom uzavřel s japonskou společností NTT DOCOMO desetiletou smlouvu na licence VMware, údržbu a technickou podporu pro privátní cloud připravený na umělou inteligenci. Finanční podmínky nebyly zveřejněny.
Semiconductor and infrastructure-software giant Broadcom
AVGO -0.48% 98
secured a 10-year VMware agreement with Japan's NTT DOCOMO, extending a major customer relationship. Shares traded at $326.075 on October 23, up approximately 0.88% at 10.45am EST on Friday. The investor question is straightforward: how much earnings power does that decade-long commitment bring?
The agreement covers software licenses, maintenance and technical support. Broadcom's announcement describes a relationship dating to 2019, with VMware Cloud Foundation underpinning DOCOMO's private cloud. The companies plan to improve reliability, security and deployment speed while preparing the platform for AI workloads. Financial terms were not disclosed, leaving investors without an annual contract value or a clear measure of its profit contribution.
The valuation snapshot puts Broadcom 24.74% below its $433.26 GF Value estimate, suggesting potential undervaluation rather than guaranteed upside. DOCOMO's commitment strengthens the customer-retention case for VMware, but contract length alone cannot establish attractive economics. The next proof points are infrastructure-software growth, cash generation and the cost of delivering support over ten years. AI readiness adds opportunity; meaningful incremental revenue still needs to follow.
Robinhood Markets (HOOD -1.56%) started with a simple idea: Make it easier for ordinary people to invest.
That sounds like a single business. But it isn't anymore. By the second quarter of 2026, Robinhood had 13 business lines generating at least $100 million of annualized revenue. That's up from just one in 2019 and nine in 2024.
At first, this might look like another impressive growth statistic. But digging deeper, I think it tells us something more important -- that Robinhood is getting better at turning one customer relationship into multiple sources of revenue.
Image source: Getty Images.
From one business to many Robinhood originally built its business around stock trading. But it didn't stop there. It kept adding products. Options became an important revenue stream. Crypto followed. Robinhood added margin lending, cash products, Gold membership subscriptions, securities lending, prediction markets, credit cards, etc. Each product gave Robinhood another way to make money from its customers.
That's an important strategy. A traditional broker might make money when a customer trades. Robinhood increasingly has opportunities to make money, whether that customer is trading, holding cash, paying for a subscription, using a card, borrowing against securities, or participating in other financial products.
The company doesn't need every product to become enormous. It needs enough of them to become meaningful. So far, that's happening.
HOOD Robinhood Markets$95.07-$1.51 (-1.56%)
NASDAQ · As of 4:00 PM ET 10/23/26
The customer matters more than the product This is where Robinhood's strategy is particularly important.
Imagine someone opens a Robinhood account to buy a few stocks. That customer might initially generate very little revenue. But over time, Robinhood can offer more products. The customer could subscribe to its Gold membership. Move more cash onto the platform. Trade options. Use the Gold Card. Buy crypto. Participate in prediction markets, and more. The customer doesn't need to find another financial company for each activity.
As for Robinhood, it can continue to expand the relationship, generating more revenue over time. Better still, it doesn't have to spend on customer acquisition costs, making growth highly efficient over time.
A few numbers show how customers are becoming more valuable. Robinhood ended the second quarter with 28.4 million funded customers, up 7% from a year earlier. Gold subscribers reached 4.8 million, up 39%, while average revenue per user increased 24% to $187.
That's an interesting combination. More customers. More products. More revenue per customer. If Robinhood can keep all three growing, the business could compound in ways that a simple trading platform cannot.
Diversification matters Another benefit of this strategy is that it reduces the volatility of Robinhood's traditional trading products. The idea is simple. Trading activity can be unpredictable. When markets become active, customers tend to trade more. When markets become quiet, transaction activity can slow.
Robinhood has gradually built other revenue streams that don't depend entirely on customers buying and selling stocks. In the second quarter, transaction-based revenue rose 44% year over year to $776 million. But Robinhood also generated $389 million of net interest revenue and $143 million of other revenue.
That mix gives the company more than one engine. If one product slows, another can potentially offset some of the weakness. That's especially valuable for a company whose original business depends heavily on market activity.
There's a catch that investors should understand, though. When Robinhood says a business has more than $100 million in annualized revenue, it doesn't mean the business generated $100 million in the past year. Robinhood calculates the figure by taking the relevant quarter's revenue and multiplying it by four. So, investors shouldn't treat the 13 businesses as 13 mature $100 million companies.
But the milestone still matters. It shows that Robinhood has created multiple products capable of reaching meaningful scale. Besides, the speed at which the company is building these products is remarkable, considering that it only had one $100 million product (options trading) in 2019.
What does it mean for investors? Robinhood has been in an expansion mode over the last few years, thanks to its strategy of building products that customers want to use. If it can continue to build products that customers want, the company could create a powerful flywheel: More customers give Robinhood a larger audience. More products give it more ways to monetize that audience.
Higher revenue gives Robinhood more resources to invest in new products. Successful products, in turn, make the platform more valuable to customers. That's how it can gradually become something much bigger.
In other words, the 13-business milestone doesn't prove Robinhood will become a great long-term compounder. But it gives investors an important clue on how the company is evolving, and that its long-term growth strategy is already gaining traction.
Akcie Chipotle v pátek klesly o 2,63 % na nové 52týdenní minimum 27,40 USD poté, co analytici snížili své cílové ceny kvůli obavám ze zpomalujícího růstu tržeb.
Chipotle Mexican Grill Inc. (NYSE:CMG) shares are sliding Friday. A fresh round of analyst price target cuts adds to concerns over slowing sales.
Chipotle Mexican Grill stock is testing key support levels. What’s pressuring CMG? Chipotle Stock Falls as Analysts Cut TargetsChipotle trades around $27.34, below its previous 52-week low of $27.87 and down from a 52-week high of $42.74. Chipotle has fallen around 2.81% today, extending a slide that totals approximately 8.50% over five days and 16.39% over a month. Over six months, the stock is down roughly 19.32%.
Evercore ISI Group analyst David Palmer lowered the price target to $40 Friday while keeping an Outperform rating.
More news today includes Mizuho analyst Nick Setyan, who also kept Outperform and brought the price target down to $37 from $43.
TD Cowen Downgrades Chipotle Over Slower SalesTD Cowen analyst Andrew Charles started the wave of cuts Wednesday with a downgrade to Hold from Buy and a lower price target of $32, down from $44.
Charles points to weak October demand as a threat to the fourth-quarter rebound that investors expect. Charles cautioned that sales are “slowing,” which raises questions about Chipotle’s ability to boost customer traffic and deliver on Wall Street’s 2027 growth hopes.
Street forecasts for 2027 call for same-store sales growth above 3%. Charles argues Chipotle may need untested levers, such as catering and more efficient restaurant equipment, to reach it, even with new menu items, marketing and loyalty programs.
Wells Fargo and Citigroup Also Cut TargetsWells Fargo analyst Zachary Fadem reduced the price target to $40 from $45 Wednesday and kept an Overweight rating. Citigroup analyst Jon Tower made a similar move Monday, lowering the target to $43 from $45 and maintaining Buy.
Benzinga’s consensus from 19 analysts is a Buy rating, with a $40.74 average target. Targets run from $32 to $53.
Chipotle releases third-quarter results on October 28, 2026. Wall Street models earnings of 29 cents per share, matching the year-ago figure, and sales climbing to $3.28 billion from $3 billion.
CMG Shares Are SlidingCMG Price Action: Chipotle shares were down 2.63% at $27.40 at the time of publication on Friday. The stock is trading at a new 52-week low, according to Benzinga Pro.
Read Next
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
Na společnost DICK'S Sporting Goods byla podána hromadná žaloba kvůli údajně zavádějícím informacím o akvizici společnosti Foot Locker; její akcie 25. srpna 2026 klesly o 30,68 %.
New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against DICK's Sporting Goods, Inc. ("Dick's Sporting Goods" or the "Company") (NYSE: DKS) on behalf of investors that purchased or otherwise acquired Dick's Sporting Goods common stock between September 8, 2025 and August 24, 2026 (the "Class Period").
CLICK HERE TO JOIN THE CASE
If you are an investor in Dick's Sporting Goods and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than November 3, 2026 for an opportunity to be lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
On September 8, 2025, the first day of the Class Period, Dick's Sporting Goods announced the completion of its acquisition of Foot Locker, Inc. ("Foot Locker") for approximately $2.5 billion in cash and stock.
The complaint alleges that throughout the Class Period, Defendants misled investors regarding the Company's acquisition of Foot Locker, touting the acquisition as a strategic opportunity to drive growth and profitability while assuring investors that Foot Locker's longstanding inventory and promotional challenges had been resolved. In reality, according to the complaint, those problems persisted, as Foot Locker remained heavily dependent on legacy footwear products that were exposed to intensifying promotional pressures across the athletic footwear industry.
The truth was allegedly revealed to investors before markets opened on August 25, 2026, when Dick's Sporting Goods reported disappointing second-quarter 2026 results, which included revenue of $1.73 billion from Foot Locker that fell well short of analysts' estimates of $1.81 billion. Dick's Sporting Goods also reduced its net sales guidance for full-year 2026 and disclosed that it expected Foot Locker's proforma comparable sales to yield a range of negative 2.0% to 0.0% for the year-down from Dick's prior forecast of 1.5% to 3% growth.
On this news, the price of Dick's Sporting Goods stock fell $55.02 per share, or 30.68%, to close at $124.31 per share on August 25, 2026.
CLICK HERE TO LEARN MORE
WHY CONTACT KAPLAN FOX?
Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.
Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.
For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.
If you have any questions about this Notice, your rights, or your interests, please contact:
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
Shares of Comfort Systems (FIX -9.48%) fell as much as 13.2% on Friday, before recovering to an 8.9% decline at 3:10 p.m. EDT.
Comfort Systems reported earnings last night, handily beating revenue and earnings estimates. However, the company also announced that one of the company's founders and longtime Chief Financial Officer, Bill George, will retire at the end of the year.
During this earnings season, even good results are leading to stock declines for most companies levered to the AI build-out. Therefore, the retirement announcement, combined with a "sell the news" mentality, appears to be the cause of today's sell-off.
FIX Comfort Systems USA$1,158.11-$121.26 (-9.48%)
NYSE · As of 3:39 PM ET 10/23/26
Comfort Systems continues to thriveComfort Systems has been a massive winner due to the AI data center build-out, given its expertise in the cooling, plumbing, ventilation, and electrical systems that AI data centers require.
Third-quarter results continued that trend, with revenue growing a whopping 53.7% and earnings per share growing an even higher 68.6% to $13.91. Both figures beat analyst expectations by a fair amount.
Not only were current results terrific, but the company's backlog grew to $17.8 billion from $14.1 billion just three months prior. That's a 26.2% quarter-over-quarter growth rate in the backlog, which would amount to a 153.7% annualized rate.
This makes Comfort Systems' sell-off all the more confusing today. However, there have been many similar sell-offs this week in AI stocks, with blockbuster earnings often met with selling pressure. It appears some investors may be anticipating the end of the AI build-out next year, even as tech executives say the opposite.
Image source: Getty Images.
Comfort Systems is reasonably priced nowComfort Systems is now about 38% off its all-time high set back in June, while shares trade at 19.4 times the average 2027 analyst earnings estimate.
That's a very reasonable valuation for Comfort Systems if the AI build-out continues beyond 2027. However, doubts over that prospect, along with the CFO's retirement announcement, appear to be dominating sentiment today.
CoStar Group očekává ve 3. čtvrtletí tržby ve výši 935–945 mil. USD, což ve středu rozpětí výhledu představuje meziroční růst o 13 %, a upravený zisk na akcii ve výši 31–34 centů.
Key Takeaways CoStar Group expects Q3 revenues to grow 13% year over year at the midpoint.
CSGP's Q3 growth is likely to benefit from strong demand and rising subscriptions.
Improving margins may aid CSGP, while Ten-X weakness and pricing pressures pose risks.
CoStar Group (CSGP - Free Report) is slated to report third-quarter 2026 results on Oct. 27.
For the third quarter of 2026, CoStar Group expects revenues to be between $935 million and $945 million, representing a 13% year-over-year increase at the midpoint, and adjusted earnings of 31-34 cents per share.
The Zacks Consensus Estimate for third-quarter 2026 revenues is currently pegged at $950.99 million, suggesting growth of 14.08% from the year-ago quarter’s levels.
The consensus mark for third-quarter 2026 earnings has been unchanged at 34 cents per share over the past 30 days, suggesting a 47.83% increase from the year-ago quarter’s figure.
CoStar Group’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 21.17%.
Let us see how things have shaped up for CSGP before the announcement.
Factors to Note Ahead of CSGP’s Q3 ResultsCoStar Group’s third-quarter performance is likely to have been driven by strong demand for its commercial real estate information and analytics solutions, growing adoption of its residential marketplaces and improving operational efficiencies.
The company’s Commercial segment is expected to have benefited from increasing subscriptions to the CoStar platform, growing adoption of CoStar Debt Solutions and strong momentum in LoopNet’s paid listings. In the second quarter of 2026, CoStar Group’s revenues increased 9% year over year to $337 million, while LoopNet revenues rose 14% to $87 million. CoStar Group’s subscriber base expanded 19% to 327,000. For the third quarter of 2026, Commercial segment revenues are projected to be between $489 million and $494 million, indicating 7% year-over-year growth at the midpoint.
Residential segment performance is expected to have benefited from continued growth in Apartments.com, Homes.com and Domain. Apartments.com is likely to have gained from increasing paid property listings and strong customer retention, while Homes.com is expected to have benefited from expanding agent subscriptions and the introduction of its Platinum advertising tier. In the second quarter, Apartments.com revenues increased 9% to $318 million, while Homes.com revenues surged 66% to $28.5 million. For the third quarter, Residential segment revenues are expected to be between $446 million and $451 million, representing 20% year-over-year growth at the midpoint.
CoStar Group’s third-quarter profitability is expected to have benefited from disciplined expense management and improving residential operating leverage. The company expects adjusted EBITDA between $190 million and $210 million, implying an adjusted EBITDA margin of approximately 21% at the midpoint, up more than 700 basis points year over year. Commercial adjusted EBITDA is projected to be between $162 million and $172 million, while residential adjusted EBITDA is expected to be between $28 million and $38 million.
However, CSGP’s third-quarter 2026 results are expected to have been hurt by declining Ten-X transaction revenues, slower near-term growth at Homes.com due to sales-force restructuring and pricing pressures at Apartments.com amid intense competition and elevated multifamily vacancies.
What Our Model Says About CSGPOur proven model does not conclusively predict an earnings beat for CoStar Group this time. Per the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. But that is not the case here.
CoStar Group presently has an Earnings ESP of 0.00% and a Zacks Rank #2. You can uncover the best stocks to buy or sell before they report earnings with our Earnings ESP Filter.
Stocks to ConsiderHere are some companies worth considering, as our model shows that these have the right combination of elements to beat on earnings in their upcoming releases:
Cadence Design Systems (CDNS - Free Report) , Seagate Technology (STX - Free Report) , and Amphenol (APH - Free Report) are some stocks with favorable combinations.
Cadence Design Systems has an Earnings ESP of +0.91% and carries a Zacks Rank #2 at present. CDNS is slated to report its third-quarter 2026 results on Oct. 26. You can see the complete list of today’s Zacks #1 Rank stocks here.
Seagate Technology has an Earnings ESP of +2.49% and sports a Zacks Rank #1 at present. Seagate Technology is set to report its first-quarter fiscal 2027 results on Oct. 27.
Amphenol has an Earnings ESP of +1.72% and a Zacks Rank #2 at present. Amphenol is set to report its third-quarter 2026 results on Oct. 28.
In This Article BTC USD: Why Does It Matter That Retail Left Futures?Are Bitcoin ETFs Still Buying?BTC USD Price Analysis: Will $79,800 Hold?One More Thing: Does the McRib Move Bitcoin? Bitcoin (BTC USD) is holding near $81,700 on Friday, October 23, after CryptoQuant CEO Ki Young Ju said retail traders have left Bitcoin futures markets. It’s the reverse of what his data showed at the 2025 top, after U.S. spot Bitcoin ETFs took in about $1 billion in three days. The price has lost $3,000 since Wednesday’s high. The buyers haven’t left.
The Bitcoin price is down 0.2% in 24 hours and 0.6% in a week. So does a quieter futures market point to a bottom, and which levels matter for BTC USD now?
Retail traders are gone from BTC futures markets, the exact opposite of what we saw at the top. https://t.co/7cdtVHsVgG pic.twitter.com/3O4lmbOfSd
— Ki Young Ju (@ki_young_ju) October 22, 2026
BTC USD: Why Does It Matter That Retail Left Futures? Because crowded markets tend to top. CryptoQuant’s chart sorts futures trades by average order size. Through the summer of 2025, with BTC between $110,000 and $120,000 ahead of its October record, small retail orders dominated almost every day. Retail kept leading as the price slid into January.
The picture is now reversed. Since May, no stretch has been led by retail. Large whale orders marked the July low near $58,000, and mid-sized whale orders drove the rally to $87,000 in September. October is mostly neutral, with whales still active.
That doesn’t mean the bottom is in. Retail also dominated from February to April 2026, when BTC was trading between $63,000 and $75,000, and BTC still fell to $58,000 by July. What it shows is that this market is less crowded with leveraged small traders, so there are fewer of them to liquidate on a drop.
Spot money agrees. U.S. spot Bitcoin ETFs took in about $1.07 billion from Monday to Wednesday, enough to turn October’s flows positive.
DISCOVER: Bitcoin ETFs Turn October Positive With $1 Billion in Three Days While ETH Funds Bleed $1 Billion
Are Bitcoin ETFs Still Buying?
Yes, and in size. U.S. spot Bitcoin ETFs took in $526.7 million on Monday, $23.2 million on Tuesday and $524.8 million on Wednesday, about $1.07 billion in three sessions. That was enough to turn October’s flows positive.
BlackRock’s IBIT led again, with $235 million on Wednesday alone. Ethereum funds went the other way and kept bleeding money.
Put the two together, and the selling this week looks like short-term traders, not long-term money heading for the exit. ETF inflows of this size have come before past rallies.
DISCOVER: Bitcoin ETFs Turn October Positive With $1 Billion in Three Days While ETH Funds Bleed $1 Billion
BTC USD Price Analysis: Will $79,800 Hold? BTC is back inside the range it has traded in since October 10, between roughly $79,800 and $84,300. Wednesday’s push to $84,898 above the top failed within a day.
The short-term damage is a broken trendline. Thursday’s drop cut through the rising line that had held every dip since the October 15 low, and BTC is now retesting it from below near $82,000.
Update: Still alive. Bitcoin doing a little bearish retest of trendline here and we can continue down to Seppuko land. https://t.co/KaNIrsKPE8 pic.twitter.com/iIObZMGEMt
— VikingXBT (@VikingXBT) October 23, 2026
Overhead, $82,000 to $82,850 is the first wall: the trendline, the swing highs and the 4-hour moving averages. A reclaim would put $84,300 back in play.
Below, $80,876 is the 50-day EMA, and $79,800, the October 15 low, is the floor of the whole range. A quick sweep under $79,800 that reverses would be a classic shakeout and the cleanest setup for a bounce. A daily close under it would point to the 200-day EMA near $76,200.
EXPLORE: J.P. Morgan Projects 10% a Year for Bitcoin: The Bank’s Own Bear Case Points to $25,000
One More Thing: Does the McRib Move Bitcoin? Crypto Twitter has a less scientific indicator for Bitcoin. McDonald’s is bringing the McRib back “as early as 10/27,” and trader internbrah reminded more than 400,000 viewers that:
BTC historically goes up >2x after the McRib returns. Don’t fade the McRib.
The McRib is back on 10/27. BTC historically goes up >2x after the McRib returns. Don't fade the McRib.
Not financial advice. pic.twitter.com/RxBuzcVht5
— internbrah (@internbrah) October 22, 2026
We checked. Of the last seven McRib returns, BTC more than doubled within a year after two, in December 2020 and November 2023. After the November 2021 return, it topped out nine days later and lost two-thirds of its value. After the November 2025 return, it never traded higher.
McRib return BTC price Best gain within 12 months October 2019 $8,246 +49% December 2020 $19,201 +252% November 2021 $61,004 +11%, then −67% October 2022 $20,496 +68% November 2023 $35,437 +106% December 2024 $96,675 +29% November 2025 $102,997 none So the McRib is two for seven on doubling, which is about what you’d expect from a sandwich. For BTC USD, $79,800 still matters more than the menu.
EXPLORE: Best Crypto Presales With Asymmetric Upside in the Current Market
#Bitcoin News Today
Why You Can Trust 99Bitcoins
10+ Years
Established in 2013, 99Bitcoins' team members have been crypto experts since Bitcoin’s early days.
90hr+
Weekly Research
100k+
Monthly Readers
50+
Expert Contributors
2000+
Crypto Projects Reviewed
Follow 99Bitcoins on your Google News Feed
Get the latest updates, trends, and insights delivered straight to your fingertips. Subscribe now!
Subscribe now
Alex Ioannou
On-Chain Journalist
Alex is a seasoned cryptocurrency trader and market analyst with over seven years of active experience in the digital asset space. Since entering the markets in 2017, Alex has specialized in identifying emerging "meta" trends and high-volatility narratives. Notably, Alex... Read More
Free Bitcoin Crash Course Enjoyed by over 100,000 students. One email a day, 7 days in a row. Short and educational, guaranteed!
Archer Aviation plánuje sítě elektrických leteckých taxíků v Austinu, Dallasu–Fort Worthu a Houstonu, které mají zkrátit cesty autem trvající 60–90 minut na lety v délce 10–20 minut.
Archer Aviation Maps Out Ambitious Air Taxi Networks Across Three Texas Cities
Summary
Archer Aviation plans to develop electric air taxi networks across Austin, Dallas–Fort Worth and Houston, aiming to cut some road journeys from over an hour to as little as 10 minutes.
Archer Aviation ACHR shares slipped about 2% in Friday morning trading despite the company outlining plans for electric air taxi networks across Austin, Dallas–Fort Worth and Houston.
The proposed routes would connect major airports with commercial centers and popular destinations across the Texas Triangle, a region home to more than 20 million people. Archer sees the networks as a potential alternative to road travel in an area facing growing traffic congestion.
The company estimates its all-electric Midnight aircraft could reduce journeys that take 60 to 90 minutes by car to flights lasting just 10 to 20 minutes. The proposed service aims to make regional transportation faster while linking key business and travel destinations.
In Dallas–Fort Worth, the network would connect six airports with business locations, including Frisco Station. Houston routes would link three airports with a downtown hotel helipad and Galveston. In Austin, planned connections include two airports and the Circuit of The Americas racing venue.
Chief Executive Adam Goldstein said the proposed networks are designed to improve connections between major destinations and reduce time spent in traffic. The company did not provide a launch timeline in the supplied information.
Disclosures
I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
Proti společnosti AST SpaceMobile (ASTS) byla podána hromadná žaloba kvůli údajně zavádějícím informacím o kapitálu a likviditě. Akcie 16. července 2026 klesly o 17,04 % na 55,01 USD.
Did you buy ASTS securities between March 4, 2025 and July 15, 2026?
Affected ASTS Investor Summary
Who: AST SpaceMobile, Inc. (NASDAQ: ASTS)What: Securities fraud class action lawsuit filedClass Period: March 4, 2025 through July 15, 2026Deadline to Seek Lead Plaintiff Status: November 13, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company’s capital and liquidity position.Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options RADNOR, Pa., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against AST SpaceMobile, Inc. (AST) (NASDAQ: ASTS) on behalf of those who purchased or acquired AST securities between March 4, 2025 and July 15, 2026, inclusive. The lawsuit is filed in the United States District Court for the Western District of Texas and is captioned Hunter v. AST SpaceMobile, Inc., No. 7:26-cv-00378 (W.D. Tex.). Investors have until November 13, 2026, to file for lead plaintiff status.
CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired AST securities and have lost money on your investment, please provide your information here:
To view the AST video on YouTube, click here: https://youtu.be/Y3ho2nK1mZo?si=UWOeZxO1resG0YuO
You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. There is no cost or obligation to speak with an attorney.
AST SPACEMOBILE, INC. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) AST’s increasing capital requirements were likely to increase the company’s debt load and share dilution with greater frequency and at greater scale than Defendants had signaled to investors; (2) accordingly, AST had overstated the sufficiency of the company’s capital and liquidity position to achieve its strategic and business goals; (3) AST likewise overstated the durability of its competitive position in the satellite D2C market; (4) even following the EchoStar Transaction, Defendants continued overstating AST’s competitive position in the satellite D2C market; (5) AST was experiencing slow user adoption in the U.S. and Japan; (6) the foregoing was likely to have a significant negative impact on AST’s business and financial prospects; and (7) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
Why did AST’s Stock Drop?
Between September 8, 2025 and July 15, 2026, a series of stock downgrades and company disclosures caused AST’s stock price to fall significantly. Specifically, on January 7, 2026, Scotiabank downgraded AST to sell, citing, among other things, significant competition from SpaceX's Starlink, slow customer adoption, and delays in launching AST's satellites. Then, on July 15, 2026, AST issued a press release "announc[ing] the pricing of $1.0 billion aggregate principal amount of 1.625% convertible senior notes due 2034". Following these disclosures, AST’s Class A common stock price fell $11.30 per share, or 17.04%, to close at $55.01 per share on July 16, 2026.
WHAT AST SPACEMOBILE, INC. INVESTORS CAN DO NOW:
File to be lead plaintiff by November 13, 2026.Contact KTMC for a free case evaluation. All representation is on a contingency fee basis, there is no cost to you.Retain counsel of choice or take no action. THE LEAD PLAINTIFF PROCESS FOR AST SPACEMOBILE, INC. INVESTORS:
AST investors may, no later than November 13, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Kessler Topaz Meltzer & Check, LLP encourages AST investors to contact the firm for more information.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500’s Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent. The complaint in this matter was not filed by KTMC.
CONTACT:
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087 [email protected]
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
